Datasets:
DylanJHJ
/
FINAL

Dataset card Data Studio Files
xet
 Community
1
idB
stringlengths
19
25
idA
stringlengths
19
25
sentA
stringlengths
24
1.82k
sentB
stringlengths
24
1.43k
type
int64
2
2
words
list
wordsA
list
wordsB
list
keywordsA
list
keywordsB
list
labels
list
probs
list
1095981_13_item7_p72_s1
1095981_12_item7_p96_s1
This price to the public in this offering was $4.50 per share and Jefferies agreed to purchase the shares from us at a price of $4.23 per share.
This price to the public in this offering was $2.85 per share and the underwriter has agreed to purchase the shares from us at a price of $2.69 per share.
2
[ "<tag1>", "This", "price", "to", "the", "public", "in", "this", "offering", "was", "$", "4.50", "per", "share", "and", "Jefferies", "agreed", "to", "purchase", "the", "shares", "from", "us", "at", "a", "price", "of", "$", "4.23", "per", "share", ".", "...
[ "This", "price", "to", "the", "public", "in", "this", "offering", "was", "$", "4.50", "per", "share", "and", "Jefferies", "agreed", "to", "purchase", "the", "shares", "from", "us", "at", "a", "price", "of", "$", "4.23", "per", "share", "." ]
[ "This", "price", "to", "the", "public", "in", "this", "offering", "was", "$", "2.85", "per", "share", "and", "the", "underwriter", "has", "agreed", "to", "purchase", "the", "shares", "from", "us", "at", "a", "price", "of", "$", "2.69", "per", "share", ...
[]
[ "2.85", "underwriter", "2.69" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, 0, -100, -100, -100, 0, -100, -100, -100, ...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, ...
1095981_14_item7_p22_s2
1095981_13_item7_p28_s2
During the year ended December 31, 2012, we incurred $331,000 in qualified expenditures.
During the year ended December 31, 2013, we incurred $3,053,000 in qualified expenditures.
2
[ "<tag1>", "During", "the", "year", "ended", "December", "31", ",", "2012", ",", "we", "incurred", "$", "331,000", "in", "qualified", "expenditures", ".", "<tag2>", "During", "the", "year", "ended", "December", "31", ",", "2013", ",", "we", "incurred", "$",...
[ "During", "the", "year", "ended", "December", "31", ",", "2012", ",", "we", "incurred", "$", "331,000", "in", "qualified", "expenditures", "." ]
[ "During", "the", "year", "ended", "December", "31", ",", "2013", ",", "we", "incurred", "$", "3,053,000", "in", "qualified", "expenditures", "." ]
[]
[ "3,053,000" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, -100, -100, 0, 0, -100, -100, -100, -100, -100, -100, -100, -100, 1, -100, -100, -100, 0, -1 ]
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1 ]
1095981_14_item7_p25_s1
1095981_13_item7_p32_s1
These expenses, in conjunction with continued development efforts related to our Celution System, result primarily from the broad expansion of our research and development efforts enabled by the funding we received from Olympus in 2005 and 2006 and from other investors during the last few years.
These expenses, in conjunction with continued development efforts related to our Celution System, result primarily from the broad expansion of our research and development efforts.
2
[ "<tag1>", "These", "expenses", ",", "in", "conjunction", "with", "continued", "development", "efforts", "related", "to", "our", "Celution", "System", ",", "result", "primarily", "from", "the", "broad", "expansion", "of", "our", "research", "and", "development", ...
[ "These", "expenses", ",", "in", "conjunction", "with", "continued", "development", "efforts", "related", "to", "our", "Celution", "System", ",", "result", "primarily", "from", "the", "broad", "expansion", "of", "our", "research", "and", "development", "efforts", ...
[ "These", "expenses", ",", "in", "conjunction", "with", "continued", "development", "efforts", "related", "to", "our", "Celution", "System", ",", "result", "primarily", "from", "the", "broad", "expansion", "of", "our", "research", "and", "development", "efforts", ...
[]
[]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, ...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, ...
1095981_14_item7_p26_s0
1095981_13_item7_p33_s0
Research and development expenses for the year ended December 31, 2012 as compared to the same period in 2011 increased due to the increase in salary and related benefits expense (excluding share-based compensation) of $949,000, an increase in professional services expenses of $393,000, increase in research supplies ex...
Research and development expenses for the year ended December 31, 2013 as compared to the same period in 2012 increased primarily due to the increase in salary and related benefits expense (excluding share-based compensation) of $590,000, an increase in professional services expenses of $1,025,000 and increase in resea...
2
[ "<tag1>", "Research", "and", "development", "expenses", "for", "the", "year", "ended", "December", "31", ",", "2012", "as", "compared", "to", "the", "same", "period", "in", "2011", "increased", "due", "to", "the", "increase", "in", "salary", "and", "related"...
[ "Research", "and", "development", "expenses", "for", "the", "year", "ended", "December", "31", ",", "2012", "as", "compared", "to", "the", "same", "period", "in", "2011", "increased", "due", "to", "the", "increase", "in", "salary", "and", "related", "benefit...
[ "Research", "and", "development", "expenses", "for", "the", "year", "ended", "December", "31", ",", "2013", "as", "compared", "to", "the", "same", "period", "in", "2012", "increased", "primarily", "due", "to", "the", "increase", "in", "salary", "and", "relat...
[]
[ "primarily", "590,000", "1,025,000", "987,000", "including", "efforts", "BARDA" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, ...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, ...
1095981_14_item7_p45_s1
1095981_13_item7_p49_s1
See Note 14 to the Consolidated Financial Statements included elsewhere herein for disclosure and discussion of share based compensation.
See Note 2 to the Consolidated Financial Statements included elsewhere herein for disclosure and discussion of our warrant liability.
2
[ "<tag1>", "See", "Note", "14", "to", "the", "Consolidated", "Financial", "Statements", "included", "elsewhere", "herein", "for", "disclosure", "and", "discussion", "of", "share", "based", "compensation", ".", "<tag2>", "See", "Note", "2", "to", "the", "Consolida...
[ "See", "Note", "14", "to", "the", "Consolidated", "Financial", "Statements", "included", "elsewhere", "herein", "for", "disclosure", "and", "discussion", "of", "share", "based", "compensation", "." ]
[ "See", "Note", "2", "to", "the", "Consolidated", "Financial", "Statements", "included", "elsewhere", "herein", "for", "disclosure", "and", "discussion", "of", "our", "warrant", "liability", "." ]
[]
[ "warrant", "liability" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, -100, -100, 0, -100, -100, -100, -100, -100, -100, 0, 0, -100, 0, -100, 0, -100, 0, 1, 1, -100, -1 ]
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1 ]
1095981_14_item7_p48_s1
1095981_13_item7_p49_s1
See Note 14 to the Consolidated Financial Statements included elsewhere herein for disclosure and discussion of share based compensation.
See Note 4 to the Consolidated Financial Statements included elsewhere herein for disclosure and discussion of our put option liability.
2
[ "<tag1>", "See", "Note", "14", "to", "the", "Consolidated", "Financial", "Statements", "included", "elsewhere", "herein", "for", "disclosure", "and", "discussion", "of", "share", "based", "compensation", ".", "<tag2>", "See", "Note", "4", "to", "the", "Consolida...
[ "See", "Note", "14", "to", "the", "Consolidated", "Financial", "Statements", "included", "elsewhere", "herein", "for", "disclosure", "and", "discussion", "of", "share", "based", "compensation", "." ]
[ "See", "Note", "4", "to", "the", "Consolidated", "Financial", "Statements", "included", "elsewhere", "herein", "for", "disclosure", "and", "discussion", "of", "our", "put", "option", "liability", "." ]
[]
[ "put", "option", "liability" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, 0, -100, -100, 0, -100, -100, -100, 0, -100, -100, 0, 0, 0, 0, 0, -100, -100, 1, 1, 1, 0, -1 ]
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1 ]
1095981_14_item7_p1_s1
1095981_13_item7_p4_s1
Adipose tissue is a rich and accessible source of ADRCs.
Adipose tissue is a rich and accessible source of stem and other regenerative cells.
2
[ "<tag1>", "Adipose", "tissue", "is", "a", "rich", "and", "accessible", "source", "of", "ADRCs", ".", "<tag2>", "Adipose", "tissue", "is", "a", "rich", "and", "accessible", "source", "of", "stem", "and", "other", "regenerative", "cells", ".", "<tag3>" ]
[ "Adipose", "tissue", "is", "a", "rich", "and", "accessible", "source", "of", "ADRCs", "." ]
[ "Adipose", "tissue", "is", "a", "rich", "and", "accessible", "source", "of", "stem", "and", "other", "regenerative", "cells", "." ]
[]
[ "stem", "regenerative", "cells" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, 0, 0, 0, 0, -100, 0, 0, 0, 0, 1, -100, -100, 1, 1, 0, -1 ]
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1 ]
1095981_14_item7_p47_s0
1095981_13_item7_p51_s0
The following is a table summarizing the change in fair value of warrant liability for the years ended December 31, 2012, 2011 and 2010:
The following is a table summarizing the change in fair value of option liability for the years ended December 31, 2013, 2012 and 2011:
2
[ "<tag1>", "The", "following", "is", "a", "table", "summarizing", "the", "change", "in", "fair", "value", "of", "warrant", "liability", "for", "the", "years", "ended", "December", "31", ",", "2012", ",", "2011", "and", "2010", ":", "<tag2>", "The", "followi...
[ "The", "following", "is", "a", "table", "summarizing", "the", "change", "in", "fair", "value", "of", "warrant", "liability", "for", "the", "years", "ended", "December", "31", ",", "2012", ",", "2011", "and", "2010", ":" ]
[ "The", "following", "is", "a", "table", "summarizing", "the", "change", "in", "fair", "value", "of", "option", "liability", "for", "the", "years", "ended", "December", "31", ",", "2013", ",", "2012", "and", "2011", ":" ]
[]
[ "option" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, -100, -100, 0, -100, -100, -100, -100, -100, -100, -100, -100, 0, ...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1 ]
1095981_14_item7_p48_s1
1095981_13_item7_p52_s1
See Note 2 to the Consolidated Condensed Financial Statements included elsewhere herein for disclosure and discussion of our warrant liability.
See Note 4 to the Consolidated Financial Statements included elsewhere herein for disclosure and discussion of our put option liability.
2
[ "<tag1>", "See", "Note", "2", "to", "the", "Consolidated", "Condensed", "Financial", "Statements", "included", "elsewhere", "herein", "for", "disclosure", "and", "discussion", "of", "our", "warrant", "liability", ".", "<tag2>", "See", "Note", "4", "to", "the", ...
[ "See", "Note", "2", "to", "the", "Consolidated", "Condensed", "Financial", "Statements", "included", "elsewhere", "herein", "for", "disclosure", "and", "discussion", "of", "our", "warrant", "liability", "." ]
[ "See", "Note", "4", "to", "the", "Consolidated", "Financial", "Statements", "included", "elsewhere", "herein", "for", "disclosure", "and", "discussion", "of", "our", "put", "option", "liability", "." ]
[]
[ "put", "option" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, 0, -100, -100, -100, -100, 0, 0, -100, 0, -100, -100, -100, -100, -100, -100, 0, 0, 1, 1, -100, ...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1 ]
1095981_14_item7_p44_s0
1095981_13_item7_p54_s0
The following is a table summarizing the change in fair value of option liability for the years ended December 31, 2012, 2011 and 2010:
The following is a table summarizing the change in fair value of warrant liability for the years ended December 31, 2013, 2012 and 2011:
2
[ "<tag1>", "The", "following", "is", "a", "table", "summarizing", "the", "change", "in", "fair", "value", "of", "option", "liability", "for", "the", "years", "ended", "December", "31", ",", "2012", ",", "2011", "and", "2010", ":", "<tag2>", "The", "followin...
[ "The", "following", "is", "a", "table", "summarizing", "the", "change", "in", "fair", "value", "of", "option", "liability", "for", "the", "years", "ended", "December", "31", ",", "2012", ",", "2011", "and", "2010", ":" ]
[ "The", "following", "is", "a", "table", "summarizing", "the", "change", "in", "fair", "value", "of", "warrant", "liability", "for", "the", "years", "ended", "December", "31", ",", "2013", ",", "2012", "and", "2011", ":" ]
[]
[ "warrant" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, 0, -100, -100, -100, -100, -100, -100, 0, -100, -100, -100, -100, ...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1 ]
1095981_14_item7_p45_s1
1095981_13_item7_p55_s1
See Note 3 to the Consolidated Condensed Financial Statements included elsewhere herein for disclosure and discussion of our put option liability.
See Note 2 to the Consolidated Financial Statements included elsewhere herein for disclosure and discussion of our warrant liability.
2
[ "<tag1>", "See", "Note", "3", "to", "the", "Consolidated", "Condensed", "Financial", "Statements", "included", "elsewhere", "herein", "for", "disclosure", "and", "discussion", "of", "our", "put", "option", "liability", ".", "<tag2>", "See", "Note", "2", "to", ...
[ "See", "Note", "3", "to", "the", "Consolidated", "Condensed", "Financial", "Statements", "included", "elsewhere", "herein", "for", "disclosure", "and", "discussion", "of", "our", "put", "option", "liability", "." ]
[ "See", "Note", "2", "to", "the", "Consolidated", "Financial", "Statements", "included", "elsewhere", "herein", "for", "disclosure", "and", "discussion", "of", "our", "warrant", "liability", "." ]
[]
[ "warrant" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, -100, -100, -100, -100, -100, 0, -100, -100, -100, -100, -100, -100, 0, -100, 0, -100, -100, 1...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1 ]
1095981_14_item7_p90_s0
1095981_13_item7_p55_s1
See Note 3 to the Consolidated Condensed Financial Statements included elsewhere herein for disclosure and discussion of our put option liability.
See Notes to Consolidated Financial Statements included elsewhere herein for disclosure and discussion of our warrant liability and our put option liability.
2
[ "<tag1>", "See", "Note", "3", "to", "the", "Consolidated", "Condensed", "Financial", "Statements", "included", "elsewhere", "herein", "for", "disclosure", "and", "discussion", "of", "our", "put", "option", "liability", ".", "<tag2>", "See", "Notes", "to", "Conso...
[ "See", "Note", "3", "to", "the", "Consolidated", "Condensed", "Financial", "Statements", "included", "elsewhere", "herein", "for", "disclosure", "and", "discussion", "of", "our", "put", "option", "liability", "." ]
[ "See", "Notes", "to", "Consolidated", "Financial", "Statements", "included", "elsewhere", "herein", "for", "disclosure", "and", "discussion", "of", "our", "warrant", "liability", "and", "our", "put", "option", "liability", "." ]
[]
[ "Notes", "warrant" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, 0, 1, -100, 0, -100, -100, 0, 0, -100, -100, -100, 0, -100, -100, -100, 1, -100, -100, -100,...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1 ]
1095981_14_item7_p56_s1
1095981_13_item7_p59_s1
Subject to our future financing activities, we expect interest expense in 2012 to remain relatively stable as we continue to pay interest on the $25.0 million term loan that was amended in September 2011.
Subject to our future financing activities, we expect interest expense in 2014 to increase slightly as we continue to pay interest on the $27.0 million term loan that was amended in June 2013.
2
[ "<tag1>", "Subject", "to", "our", "future", "financing", "activities", ",", "we", "expect", "interest", "expense", "in", "2012", "to", "remain", "relatively", "stable", "as", "we", "continue", "to", "pay", "interest", "on", "the", "$", "25.0", "million", "te...
[ "Subject", "to", "our", "future", "financing", "activities", ",", "we", "expect", "interest", "expense", "in", "2012", "to", "remain", "relatively", "stable", "as", "we", "continue", "to", "pay", "interest", "on", "the", "$", "25.0", "million", "term", "loan...
[ "Subject", "to", "our", "future", "financing", "activities", ",", "we", "expect", "interest", "expense", "in", "2014", "to", "increase", "slightly", "as", "we", "continue", "to", "pay", "interest", "on", "the", "$", "27.0", "million", "term", "loan", "that",...
[]
[ "increase", "slightly", "27.0", "June", "2013" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, -100, ...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, ...
1095981_14_item7_p2_s1
1095981_13_item7_p5_s1
The early sales of systems, consumables and ancillary products contributes margins that partially offset our operating expenses and play an important strategic role in fostering familiarity within the medical community with our technology and to facilitate the discovery of potential new applications for Cytori s cell t...
The early sales of systems, consumables and ancillary products contributes margins that partially offset our operating expenses and play an important strategic role in fostering familiarity within the medical community with our technology.
2
[ "<tag1>", "The", "early", "sales", "of", "systems", ",", "consumables", "and", "ancillary", "products", "contributes", "margins", "that", "partially", "offset", "our", "operating", "expenses", "and", "play", "an", "important", "strategic", "role", "in", "fostering...
[ "The", "early", "sales", "of", "systems", ",", "consumables", "and", "ancillary", "products", "contributes", "margins", "that", "partially", "offset", "our", "operating", "expenses", "and", "play", "an", "important", "strategic", "role", "in", "fostering", "famili...
[ "The", "early", "sales", "of", "systems", ",", "consumables", "and", "ancillary", "products", "contributes", "margins", "that", "partially", "offset", "our", "operating", "expenses", "and", "play", "an", "important", "strategic", "role", "in", "fostering", "famili...
[]
[]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, ...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, ...
1095981_14_item7_p70_s1
1095981_13_item7_p69_s1
This price to the public in this offering was $4.50 per share and Jefferies agreed to purchase the shares from us at a price of $4.23 per share.
This price to the public in this offering was $2.85 per share and the underwriter purchased the shares from us at a price of $2.69 per share.
2
[ "<tag1>", "This", "price", "to", "the", "public", "in", "this", "offering", "was", "$", "4.50", "per", "share", "and", "Jefferies", "agreed", "to", "purchase", "the", "shares", "from", "us", "at", "a", "price", "of", "$", "4.23", "per", "share", ".", "...
[ "This", "price", "to", "the", "public", "in", "this", "offering", "was", "$", "4.50", "per", "share", "and", "Jefferies", "agreed", "to", "purchase", "the", "shares", "from", "us", "at", "a", "price", "of", "$", "4.23", "per", "share", "." ]
[ "This", "price", "to", "the", "public", "in", "this", "offering", "was", "$", "2.85", "per", "share", "and", "the", "underwriter", "purchased", "the", "shares", "from", "us", "at", "a", "price", "of", "$", "2.69", "per", "share", "." ]
[]
[ "2.85", "underwriter", "purchased", "2.69" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, 0, -100, 0, 0, -100, 0, -100, -100, -100...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, ...
1095981_14_item7_p67_s1
1095981_13_item7_p72_s1
This price to the public in this offering was $2.85 per share and the underwriter has agreed to purchase the shares from us at a price of $2.69 per share.
This price to the public in this offering was $4.50 per share and Jefferies agreed to purchase the shares from us at a price of $4.23 per share.
2
[ "<tag1>", "This", "price", "to", "the", "public", "in", "this", "offering", "was", "$", "2.85", "per", "share", "and", "the", "underwriter", "has", "agreed", "to", "purchase", "the", "shares", "from", "us", "at", "a", "price", "of", "$", "2.69", "per", ...
[ "This", "price", "to", "the", "public", "in", "this", "offering", "was", "$", "2.85", "per", "share", "and", "the", "underwriter", "has", "agreed", "to", "purchase", "the", "shares", "from", "us", "at", "a", "price", "of", "$", "2.69", "per", "share", ...
[ "This", "price", "to", "the", "public", "in", "this", "offering", "was", "$", "4.50", "per", "share", "and", "Jefferies", "agreed", "to", "purchase", "the", "shares", "from", "us", "at", "a", "price", "of", "$", "4.23", "per", "share", "." ]
[]
[ "4.50", "Jefferies", "4.23" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, 0, 0, -100, -100, 0, -100, -...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, ...
1095981_14_item7_p48_s1
1095981_13_item7_p86_s0
See Notes to Consolidated Condensed Financial Statements included elsewhere herein for disclosure and discussion of our warrant liability and our put option liability.
See Note 4 to the Consolidated Financial Statements included elsewhere herein for disclosure and discussion of our put option liability.
2
[ "<tag1>", "See", "Notes", "to", "Consolidated", "Condensed", "Financial", "Statements", "included", "elsewhere", "herein", "for", "disclosure", "and", "discussion", "of", "our", "warrant", "liability", "and", "our", "put", "option", "liability", ".", "<tag2>", "Se...
[ "See", "Notes", "to", "Consolidated", "Condensed", "Financial", "Statements", "included", "elsewhere", "herein", "for", "disclosure", "and", "discussion", "of", "our", "warrant", "liability", "and", "our", "put", "option", "liability", "." ]
[ "See", "Note", "4", "to", "the", "Consolidated", "Financial", "Statements", "included", "elsewhere", "herein", "for", "disclosure", "and", "discussion", "of", "our", "put", "option", "liability", "." ]
[]
[ "Note", "4" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, 0, 1, 1, -100, 0, 0, -100, -100, -100, 0, -100, -100, 0, -100, -100, 0, -100, ...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1 ]
1095981_14_item7_p92_s0
1095981_13_item7_p87_s0
See Notes to Consolidated Condensed Financial Statements included elsewhere herein for disclosure and discussion of revenue recognition.
See Notes to Consolidated Financial Statements included elsewhere herein for disclosure and discussion of stock-based compensation.
2
[ "<tag1>", "See", "Notes", "to", "Consolidated", "Condensed", "Financial", "Statements", "included", "elsewhere", "herein", "for", "disclosure", "and", "discussion", "of", "revenue", "recognition", ".", "<tag2>", "See", "Notes", "to", "Consolidated", "Financial", "St...
[ "See", "Notes", "to", "Consolidated", "Condensed", "Financial", "Statements", "included", "elsewhere", "herein", "for", "disclosure", "and", "discussion", "of", "revenue", "recognition", "." ]
[ "See", "Notes", "to", "Consolidated", "Financial", "Statements", "included", "elsewhere", "herein", "for", "disclosure", "and", "discussion", "of", "stock", "-", "based", "compensation", "." ]
[]
[ "stock", "based", "compensation" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, 0, -100, -100, 0, 0, -100, 0, -100, 0, -100, 0, 0, 0, -100, 1, -100, 1, 1, 0, -1 ]
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1 ]
1095981_14_item7_p93_s0
1095981_13_item7_p87_s0
See Notes to Consolidated Condensed Financial Statements included elsewhere herein for disclosure and discussion of revenue recognition.
See Notes to Consolidated Financial Statements included elsewhere herein for disclosure and discussion of new accounting standards.
2
[ "<tag1>", "See", "Notes", "to", "Consolidated", "Condensed", "Financial", "Statements", "included", "elsewhere", "herein", "for", "disclosure", "and", "discussion", "of", "revenue", "recognition", ".", "<tag2>", "See", "Notes", "to", "Consolidated", "Financial", "St...
[ "See", "Notes", "to", "Consolidated", "Condensed", "Financial", "Statements", "included", "elsewhere", "herein", "for", "disclosure", "and", "discussion", "of", "revenue", "recognition", "." ]
[ "See", "Notes", "to", "Consolidated", "Financial", "Statements", "included", "elsewhere", "herein", "for", "disclosure", "and", "discussion", "of", "new", "accounting", "standards", "." ]
[]
[ "new", "accounting", "standards" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, 0, 0, 0, -100, 0, -100, 0, 0, 0, 0, -100, -100, -100, -100, 1, 1, 1, 0, -1 ]
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1 ]
1095981_14_item7_p91_s0
1095981_13_item7_p88_s0
See Notes to Consolidated Condensed Financial Statements included elsewhere herein for disclosure and discussion of stock-based compensation.
See Notes to Consolidated Financial Statements included elsewhere herein for disclosure and discussion of revenue recognition.
2
[ "<tag1>", "See", "Notes", "to", "Consolidated", "Condensed", "Financial", "Statements", "included", "elsewhere", "herein", "for", "disclosure", "and", "discussion", "of", "stock", "-", "based", "compensation", ".", "<tag2>", "See", "Notes", "to", "Consolidated", "...
[ "See", "Notes", "to", "Consolidated", "Condensed", "Financial", "Statements", "included", "elsewhere", "herein", "for", "disclosure", "and", "discussion", "of", "stock", "-", "based", "compensation", "." ]
[ "See", "Notes", "to", "Consolidated", "Financial", "Statements", "included", "elsewhere", "herein", "for", "disclosure", "and", "discussion", "of", "revenue", "recognition", "." ]
[]
[ "revenue", "recognition" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, -100, -100, -100, 0, -100, 0, 0, -100, -100, 0, -100, 0, -100, 0, 1, 1, -100, -1 ]
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1 ]
1095981_14_item7_p93_s0
1095981_13_item7_p88_s0
See Notes to Consolidated Condensed Financial Statements included elsewhere herein for disclosure and discussion of stock-based compensation.
See Notes to Consolidated Financial Statements included elsewhere herein for disclosure and discussion of new accounting standards.
2
[ "<tag1>", "See", "Notes", "to", "Consolidated", "Condensed", "Financial", "Statements", "included", "elsewhere", "herein", "for", "disclosure", "and", "discussion", "of", "stock", "-", "based", "compensation", ".", "<tag2>", "See", "Notes", "to", "Consolidated", "...
[ "See", "Notes", "to", "Consolidated", "Condensed", "Financial", "Statements", "included", "elsewhere", "herein", "for", "disclosure", "and", "discussion", "of", "stock", "-", "based", "compensation", "." ]
[ "See", "Notes", "to", "Consolidated", "Financial", "Statements", "included", "elsewhere", "herein", "for", "disclosure", "and", "discussion", "of", "new", "accounting", "standards", "." ]
[]
[ "new", "accounting", "standards" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, -100, -100, 0, 0, -100, 0, 0, 0, -100, 0, 0, -100, 0, 0, 1, 1, 1, -100, -1 ]
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1 ]
1095981_14_item7_p90_s0
1095981_13_item7_p89_s0
See Notes to Consolidated Financial Statements included elsewhere herein for disclosure and discussion of new accounting standards.
See Notes to Consolidated Financial Statements included elsewhere herein for disclosure and discussion of our warrant liability and our put option liability.
2
[ "<tag1>", "See", "Notes", "to", "Consolidated", "Financial", "Statements", "included", "elsewhere", "herein", "for", "disclosure", "and", "discussion", "of", "new", "accounting", "standards", ".", "<tag2>", "See", "Notes", "to", "Consolidated", "Financial", "Stateme...
[ "See", "Notes", "to", "Consolidated", "Financial", "Statements", "included", "elsewhere", "herein", "for", "disclosure", "and", "discussion", "of", "new", "accounting", "standards", "." ]
[ "See", "Notes", "to", "Consolidated", "Financial", "Statements", "included", "elsewhere", "herein", "for", "disclosure", "and", "discussion", "of", "our", "warrant", "liability", "and", "our", "put", "option", "liability", "." ]
[]
[ "warrant", "liability", "put", "option", "liability" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, 0, 0, 0, 0, 0, 0, 0, -100, -100, 0, 0, 0, 0, 0, 0, 1, 1, 0, 0, 1, 1, 1, -100, -1 ]
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1 ]
1095981_14_item7_p91_s0
1095981_13_item7_p89_s0
See Notes to Consolidated Financial Statements included elsewhere herein for disclosure and discussion of new accounting standards.
See Notes to Consolidated Financial Statements included elsewhere herein for disclosure and discussion of revenue recognition.
2
[ "<tag1>", "See", "Notes", "to", "Consolidated", "Financial", "Statements", "included", "elsewhere", "herein", "for", "disclosure", "and", "discussion", "of", "new", "accounting", "standards", ".", "<tag2>", "See", "Notes", "to", "Consolidated", "Financial", "Stateme...
[ "See", "Notes", "to", "Consolidated", "Financial", "Statements", "included", "elsewhere", "herein", "for", "disclosure", "and", "discussion", "of", "new", "accounting", "standards", "." ]
[ "See", "Notes", "to", "Consolidated", "Financial", "Statements", "included", "elsewhere", "herein", "for", "disclosure", "and", "discussion", "of", "revenue", "recognition", "." ]
[]
[ "revenue", "recognition" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, -100, 0, 0, 0, -100, 0, -100, -100, -100, -100, 0, -100, 0, -100, 1, 1, -100, -1 ]
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1 ]
1095981_14_item7_p92_s0
1095981_13_item7_p89_s0
See Notes to Consolidated Financial Statements included elsewhere herein for disclosure and discussion of new accounting standards.
See Notes to Consolidated Financial Statements included elsewhere herein for disclosure and discussion of stock-based compensation.
2
[ "<tag1>", "See", "Notes", "to", "Consolidated", "Financial", "Statements", "included", "elsewhere", "herein", "for", "disclosure", "and", "discussion", "of", "new", "accounting", "standards", ".", "<tag2>", "See", "Notes", "to", "Consolidated", "Financial", "Stateme...
[ "See", "Notes", "to", "Consolidated", "Financial", "Statements", "included", "elsewhere", "herein", "for", "disclosure", "and", "discussion", "of", "new", "accounting", "standards", "." ]
[ "See", "Notes", "to", "Consolidated", "Financial", "Statements", "included", "elsewhere", "herein", "for", "disclosure", "and", "discussion", "of", "stock", "-", "based", "compensation", "." ]
[]
[ "stock", "based", "compensation" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, -100, 0, -100, 0, 0, -100, 0, -100, -100, -100, 0, 0, 0, -100, 1, 0, 1, 1, 0, -1 ]
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1 ]
1095981_14_item7_p4_s0
1095981_13_item7_p9_s0
In the U.S., we are conducting our ATHENA trial, a prospective, double blind, placebo-controlled, multi-center trial in up to 45 patients.
In the U.S., we are conducting our ATHENA trial, a prospective, double blind, placebo-controlled, multi-center trial in up to 45 patients with ischemic heart disease.
2
[ "<tag1>", "In", "the", "U.S.", ",", "we", "are", "conducting", "our", "ATHENA", "trial", ",", "a", "prospective", ",", "double", "blind", ",", "placebo", "-", "controlled", ",", "multi", "-", "center", "trial", "in", "up", "to", "45", "patients", ".", ...
[ "In", "the", "U.S.", ",", "we", "are", "conducting", "our", "ATHENA", "trial", ",", "a", "prospective", ",", "double", "blind", ",", "placebo", "-", "controlled", ",", "multi", "-", "center", "trial", "in", "up", "to", "45", "patients", "." ]
[ "In", "the", "U.S.", ",", "we", "are", "conducting", "our", "ATHENA", "trial", ",", "a", "prospective", ",", "double", "blind", ",", "placebo", "-", "controlled", ",", "multi", "-", "center", "trial", "in", "up", "to", "45", "patients", "with", "ischemic...
[]
[ "ischemic", "heart", "disease" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, 0, -100, -100, -100, -100, -100, -100, 0, ...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, ...
1095981_14_item7_p4_s2
1095981_13_item7_p9_s2
Additional endpoints include perfusion defect, left ventricle end-systolic and diastolic volume and ejection fraction at six and 12 months.
Additional endpoints include perfusion defect, left ventricle end-systolic and diastolic volume and ejection fraction at six and 12 months, NYHA functional class and health-related quality of life.
2
[ "<tag1>", "Additional", "endpoints", "include", "perfusion", "defect", ",", "left", "ventricle", "end", "-", "systolic", "and", "diastolic", "volume", "and", "ejection", "fraction", "at", "six", "and", "12", "months", ".", "<tag2>", "Additional", "endpoints", "i...
[ "Additional", "endpoints", "include", "perfusion", "defect", ",", "left", "ventricle", "end", "-", "systolic", "and", "diastolic", "volume", "and", "ejection", "fraction", "at", "six", "and", "12", "months", "." ]
[ "Additional", "endpoints", "include", "perfusion", "defect", ",", "left", "ventricle", "end", "-", "systolic", "and", "diastolic", "volume", "and", "ejection", "fraction", "at", "six", "and", "12", "months", ",", "NYHA", "functional", "class", "and", "health", ...
[]
[ "NYHA", "functional", "class", "health", "related", "quality", "life" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, 0, 0, -100, -100, -100, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1 ]
1095981_15_item7_p21_s2
1095981_14_item7_p22_s5
We recognized a total of $355,000 in revenues for the year ended December 31, 2012, which included allowable fees as well as cost reimbursements.
During the year ended December 31, 2012, we incurred $331,000 in qualified expenditures, and recognized a total of $355,000 in revenues, which included allowable fees as well as cost reimbursements.
2
[ "<tag1>", "We", "recognized", "a", "total", "of", "$", "355,000", "in", "revenues", "for", "the", "year", "ended", "December", "31", ",", "2012", ",", "which", "included", "allowable", "fees", "as", "well", "as", "cost", "reimbursements", ".", "<tag2>", "D...
[ "We", "recognized", "a", "total", "of", "$", "355,000", "in", "revenues", "for", "the", "year", "ended", "December", "31", ",", "2012", ",", "which", "included", "allowable", "fees", "as", "well", "as", "cost", "reimbursements", "." ]
[ "During", "the", "year", "ended", "December", "31", ",", "2012", ",", "we", "incurred", "$", "331,000", "in", "qualified", "expenditures", ",", "and", "recognized", "a", "total", "of", "$", "355,000", "in", "revenues", ",", "which", "included", "allowable", ...
[]
[ "incurred", "331,000", "qualified", "expenditures" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, 0, -100, -100, 0, -100, 0, -100, -100, -100, 0, 1, -100, ...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, ...
1095981_15_item7_p109_s0
1095981_14_item7_p41_s1
See Note 16 to the Consolidated Financial Statements included elsewhere herein for disclosure and discussion of share based compensation.
See Note 2 to the Consolidated Financial Statements included elsewhere herein for disclosure and discussion of new accounting standards.
2
[ "<tag1>", "See", "Note", "16", "to", "the", "Consolidated", "Financial", "Statements", "included", "elsewhere", "herein", "for", "disclosure", "and", "discussion", "of", "share", "based", "compensation", ".", "<tag2>", "See", "Note", "2", "to", "the", "Consolida...
[ "See", "Note", "16", "to", "the", "Consolidated", "Financial", "Statements", "included", "elsewhere", "herein", "for", "disclosure", "and", "discussion", "of", "share", "based", "compensation", "." ]
[ "See", "Note", "2", "to", "the", "Consolidated", "Financial", "Statements", "included", "elsewhere", "herein", "for", "disclosure", "and", "discussion", "of", "new", "accounting", "standards", "." ]
[]
[ "new", "accounting", "standards" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, 0, -100, 0, 0, 0, -100, 0, 0, -100, 0, 0, -100, -100, -100, 0, -100, 1, 1, 1, -100, -1 ]
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1 ]
1095981_15_item7_p109_s0
1095981_14_item7_p42_s1
See Note 16 to the Consolidated Financial Statements included elsewhere herein for disclosure and discussion of share based compensation.
See Note 2 to the Consolidated Financial Statements included elsewhere herein for disclosure and discussion of new accounting standards.
2
[ "<tag1>", "See", "Note", "16", "to", "the", "Consolidated", "Financial", "Statements", "included", "elsewhere", "herein", "for", "disclosure", "and", "discussion", "of", "share", "based", "compensation", ".", "<tag2>", "See", "Note", "2", "to", "the", "Consolida...
[ "See", "Note", "16", "to", "the", "Consolidated", "Financial", "Statements", "included", "elsewhere", "herein", "for", "disclosure", "and", "discussion", "of", "share", "based", "compensation", "." ]
[ "See", "Note", "2", "to", "the", "Consolidated", "Financial", "Statements", "included", "elsewhere", "herein", "for", "disclosure", "and", "discussion", "of", "new", "accounting", "standards", "." ]
[]
[ "new", "accounting", "standards" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, -100, -100, -100, 0, 0, -100, 0, -100, 0, -100, 0, 0, -100, 0, 0, -100, 1, 1, 1, 0, -1 ]
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1 ]
1095981_15_item7_p47_s0
1095981_14_item7_p44_s0
The following is a table summarizing the change in fair value of warrant liability for the years ended December 31, 2013, 2012 and 2011:
The following is a table summarizing the change in fair value of option liability for the years ended December 31, 2014, 2013 and 2012:
2
[ "<tag1>", "The", "following", "is", "a", "table", "summarizing", "the", "change", "in", "fair", "value", "of", "warrant", "liability", "for", "the", "years", "ended", "December", "31", ",", "2013", ",", "2012", "and", "2011", ":", "<tag2>", "The", "followi...
[ "The", "following", "is", "a", "table", "summarizing", "the", "change", "in", "fair", "value", "of", "warrant", "liability", "for", "the", "years", "ended", "December", "31", ",", "2013", ",", "2012", "and", "2011", ":" ]
[ "The", "following", "is", "a", "table", "summarizing", "the", "change", "in", "fair", "value", "of", "option", "liability", "for", "the", "years", "ended", "December", "31", ",", "2014", ",", "2013", "and", "2012", ":" ]
[]
[ "option" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, -100, 0, -100, -100, -100, 0, -100, -100, -100, -100, -100, -100, ...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1 ]
1095981_15_item7_p109_s0
1095981_14_item7_p45_s1
See Note 2 to the Consolidated Financial Statements included elsewhere herein for disclosure and discussion of our warrant liability.
See Note 2 to the Consolidated Financial Statements included elsewhere herein for disclosure and discussion of new accounting standards.
2
[ "<tag1>", "See", "Note", "2", "to", "the", "Consolidated", "Financial", "Statements", "included", "elsewhere", "herein", "for", "disclosure", "and", "discussion", "of", "our", "warrant", "liability", ".", "<tag2>", "See", "Note", "2", "to", "the", "Consolidated"...
[ "See", "Note", "2", "to", "the", "Consolidated", "Financial", "Statements", "included", "elsewhere", "herein", "for", "disclosure", "and", "discussion", "of", "our", "warrant", "liability", "." ]
[ "See", "Note", "2", "to", "the", "Consolidated", "Financial", "Statements", "included", "elsewhere", "herein", "for", "disclosure", "and", "discussion", "of", "new", "accounting", "standards", "." ]
[]
[ "new", "accounting", "standards" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, -100, -100, 0, 0, -100, 0, -100, 0, -100, 0, 0, -100, -100, 0, -100, 0, 1, 1, 1, 0, -1 ]
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1 ]
1095981_15_item7_p41_s1
1095981_14_item7_p45_s1
See Note 2 to the Consolidated Financial Statements included elsewhere herein for disclosure and discussion of our warrant liability.
See Note 16 to the Consolidated Financial Statements included elsewhere herein for disclosure and discussion of share-based compensation.
2
[ "<tag1>", "See", "Note", "2", "to", "the", "Consolidated", "Financial", "Statements", "included", "elsewhere", "herein", "for", "disclosure", "and", "discussion", "of", "our", "warrant", "liability", ".", "<tag2>", "See", "Note", "16", "to", "the", "Consolidated...
[ "See", "Note", "2", "to", "the", "Consolidated", "Financial", "Statements", "included", "elsewhere", "herein", "for", "disclosure", "and", "discussion", "of", "our", "warrant", "liability", "." ]
[ "See", "Note", "16", "to", "the", "Consolidated", "Financial", "Statements", "included", "elsewhere", "herein", "for", "disclosure", "and", "discussion", "of", "share", "-", "based", "compensation", "." ]
[]
[ "share", "based", "compensation" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, 0, 0, 0, -100, 0, -100, 0, -100, -100, 0, -100, -100, -100, -100, 0, 0, 1, -100, 1, 1, 0, -1 ]
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1 ]
1095981_15_item7_p42_s1
1095981_14_item7_p45_s1
See Note 2 to the Consolidated Financial Statements included elsewhere herein for disclosure and discussion of our warrant liability.
See Note 16 to the Consolidated Financial Statements included elsewhere herein for disclosure and discussion of share-based compensation.
2
[ "<tag1>", "See", "Note", "2", "to", "the", "Consolidated", "Financial", "Statements", "included", "elsewhere", "herein", "for", "disclosure", "and", "discussion", "of", "our", "warrant", "liability", ".", "<tag2>", "See", "Note", "16", "to", "the", "Consolidated...
[ "See", "Note", "2", "to", "the", "Consolidated", "Financial", "Statements", "included", "elsewhere", "herein", "for", "disclosure", "and", "discussion", "of", "our", "warrant", "liability", "." ]
[ "See", "Note", "16", "to", "the", "Consolidated", "Financial", "Statements", "included", "elsewhere", "herein", "for", "disclosure", "and", "discussion", "of", "share", "-", "based", "compensation", "." ]
[]
[ "share", "based", "compensation" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, 0, 0, -100, -100, 0, 0, 0, -100, 0, 0, -100, -100, -100, 0, -100, 0, 1, -100, 1, 1, -100, -1 ]
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1 ]
1095981_15_item7_p44_s0
1095981_14_item7_p47_s0
The following is a table summarizing the change in fair value of option liability for the years ended December 31, 2013, 2012 and 2011:
The following is a table summarizing the change in fair value of warrant liability for the years ended December 31, 2014, 2013 and 2012:
2
[ "<tag1>", "The", "following", "is", "a", "table", "summarizing", "the", "change", "in", "fair", "value", "of", "option", "liability", "for", "the", "years", "ended", "December", "31", ",", "2013", ",", "2012", "and", "2011", ":", "<tag2>", "The", "followin...
[ "The", "following", "is", "a", "table", "summarizing", "the", "change", "in", "fair", "value", "of", "option", "liability", "for", "the", "years", "ended", "December", "31", ",", "2013", ",", "2012", "and", "2011", ":" ]
[ "The", "following", "is", "a", "table", "summarizing", "the", "change", "in", "fair", "value", "of", "warrant", "liability", "for", "the", "years", "ended", "December", "31", ",", "2014", ",", "2013", "and", "2012", ":" ]
[]
[ "warrant" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, -100, 0, -100, -100, -100, -100, -100, -100, -100, 0, -100, -100, ...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1 ]
1095981_15_item7_p109_s0
1095981_14_item7_p48_s1
See Note 4 to the Consolidated Financial Statements included elsewhere herein for disclosure and discussion of our put option liability.
See Note 2 to the Consolidated Financial Statements included elsewhere herein for disclosure and discussion of new accounting standards.
2
[ "<tag1>", "See", "Note", "4", "to", "the", "Consolidated", "Financial", "Statements", "included", "elsewhere", "herein", "for", "disclosure", "and", "discussion", "of", "our", "put", "option", "liability", ".", "<tag2>", "See", "Note", "2", "to", "the", "Conso...
[ "See", "Note", "4", "to", "the", "Consolidated", "Financial", "Statements", "included", "elsewhere", "herein", "for", "disclosure", "and", "discussion", "of", "our", "put", "option", "liability", "." ]
[ "See", "Note", "2", "to", "the", "Consolidated", "Financial", "Statements", "included", "elsewhere", "herein", "for", "disclosure", "and", "discussion", "of", "new", "accounting", "standards", "." ]
[]
[ "new", "accounting", "standards" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, 0, -100, 0, 0, -100, 0, 0, 0, -100, -100, 0, 0, -100, 0, -100, -100, 1, 1, 1, -100, -1 ]
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1 ]
1095981_15_item7_p41_s1
1095981_14_item7_p48_s1
See Note 4 to the Consolidated Financial Statements included elsewhere herein for disclosure and discussion of our put option liability.
See Note 16 to the Consolidated Financial Statements included elsewhere herein for disclosure and discussion of share-based compensation.
2
[ "<tag1>", "See", "Note", "4", "to", "the", "Consolidated", "Financial", "Statements", "included", "elsewhere", "herein", "for", "disclosure", "and", "discussion", "of", "our", "put", "option", "liability", ".", "<tag2>", "See", "Note", "16", "to", "the", "Cons...
[ "See", "Note", "4", "to", "the", "Consolidated", "Financial", "Statements", "included", "elsewhere", "herein", "for", "disclosure", "and", "discussion", "of", "our", "put", "option", "liability", "." ]
[ "See", "Note", "16", "to", "the", "Consolidated", "Financial", "Statements", "included", "elsewhere", "herein", "for", "disclosure", "and", "discussion", "of", "share", "-", "based", "compensation", "." ]
[]
[ "share", "based", "compensation" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, -100, -100, -100, -100, -100, 0, 0, -100, 0, -100, 0, 0, -100, 0, 0, 0, 1, -100, 1, 1, 0, -1 ]
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1 ]
1095981_15_item7_p42_s1
1095981_14_item7_p48_s1
See Note 4 to the Consolidated Financial Statements included elsewhere herein for disclosure and discussion of our put option liability.
See Note 16 to the Consolidated Financial Statements included elsewhere herein for disclosure and discussion of share-based compensation.
2
[ "<tag1>", "See", "Note", "4", "to", "the", "Consolidated", "Financial", "Statements", "included", "elsewhere", "herein", "for", "disclosure", "and", "discussion", "of", "our", "put", "option", "liability", ".", "<tag2>", "See", "Note", "16", "to", "the", "Cons...
[ "See", "Note", "4", "to", "the", "Consolidated", "Financial", "Statements", "included", "elsewhere", "herein", "for", "disclosure", "and", "discussion", "of", "our", "put", "option", "liability", "." ]
[ "See", "Note", "16", "to", "the", "Consolidated", "Financial", "Statements", "included", "elsewhere", "herein", "for", "disclosure", "and", "discussion", "of", "share", "-", "based", "compensation", "." ]
[]
[ "share", "based", "compensation" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, 0, -100, -100, 0, 0, -100, 0, -100, 0, 0, -100, -100, -100, 0, -100, -100, 1, 0, 1, 1, 0, -1 ]
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1 ]
1095981_15_item7_p59_s1
1095981_14_item7_p61_s1
We have an accumulated deficit of $300,905,000 as of December 31, 2013.
We have an accumulated deficit of $338,273,000 as of December 31, 2014.
2
[ "<tag1>", "We", "have", "an", "accumulated", "deficit", "of", "$", "300,905,000", "as", "of", "December", "31", ",", "2013", ".", "<tag2>", "We", "have", "an", "accumulated", "deficit", "of", "$", "338,273,000", "as", "of", "December", "31", ",", "2014", ...
[ "We", "have", "an", "accumulated", "deficit", "of", "$", "300,905,000", "as", "of", "December", "31", ",", "2013", "." ]
[ "We", "have", "an", "accumulated", "deficit", "of", "$", "338,273,000", "as", "of", "December", "31", ",", "2014", "." ]
[]
[ "338,273,000" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, -100, -100, -100, 0, -100, -100, -100, 1, -100, -100, 0, -100, -100, 0, -100, -1 ]
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1 ]
1095981_15_item7_p64_s1
1095981_14_item7_p67_s1
This price to the public in this offering was $4.50 per share and Jefferies agreed to purchase the shares from us at a price of $4.23 per share.
This price to the public in this offering was $2.85 per share and the underwriter purchased the shares from us at a price of $2.69 per share.
2
[ "<tag1>", "This", "price", "to", "the", "public", "in", "this", "offering", "was", "$", "4.50", "per", "share", "and", "Jefferies", "agreed", "to", "purchase", "the", "shares", "from", "us", "at", "a", "price", "of", "$", "4.23", "per", "share", ".", "...
[ "This", "price", "to", "the", "public", "in", "this", "offering", "was", "$", "4.50", "per", "share", "and", "Jefferies", "agreed", "to", "purchase", "the", "shares", "from", "us", "at", "a", "price", "of", "$", "4.23", "per", "share", "." ]
[ "This", "price", "to", "the", "public", "in", "this", "offering", "was", "$", "2.85", "per", "share", "and", "the", "underwriter", "purchased", "the", "shares", "from", "us", "at", "a", "price", "of", "$", "2.69", "per", "share", "." ]
[]
[ "2.85", "underwriter", "purchased", "2.69" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, 0, 0, -100, -100, -100, -100, 0, 0, 0, ...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, ...
1095981_15_item7_p70_s2
1095981_14_item7_p76_s2
Pursuant to the related Common Stock Purchase Agreement, Cytori has received $24 million in exchange for 8 million shares of Cytori common stock at $3.00 per share.
Pursuant to the related Common Stock Purchase Agreement, we received $24.0 million in exchange for 8.0 million shares of our common stock issued to Lorem Vascular at $3.00 per share.
2
[ "<tag1>", "Pursuant", "to", "the", "related", "Common", "Stock", "Purchase", "Agreement", ",", "Cytori", "has", "received", "$", "24", "million", "in", "exchange", "for", "8", "million", "shares", "of", "Cytori", "common", "stock", "at", "$", "3.00", "per", ...
[ "Pursuant", "to", "the", "related", "Common", "Stock", "Purchase", "Agreement", ",", "Cytori", "has", "received", "$", "24", "million", "in", "exchange", "for", "8", "million", "shares", "of", "Cytori", "common", "stock", "at", "$", "3.00", "per", "share", ...
[ "Pursuant", "to", "the", "related", "Common", "Stock", "Purchase", "Agreement", ",", "we", "received", "$", "24.0", "million", "in", "exchange", "for", "8.0", "million", "shares", "of", "our", "common", "stock", "issued", "to", "Lorem", "Vascular", "at", "$"...
[]
[ "24.0", "8.0", "issued", "Lorem", "Vascular" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, 0, -100, 0, 0, -100, 0, -100, 0, -100, ...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, ...
1095981_15_item7_p80_s1
1095981_14_item7_p79_s1
The operating cash impact of this loss was $34,563,000, after adjusting for the recognition of non-cash development revenues of $1,817,000, the consideration of non-cash share-based compensation, other adjustments for material non-cash activities, such as depreciation, amortization, change in fair value of option liabi...
The operating cash impact of this loss was $30,330,000, after adjusting for non-cash share-based compensation, other adjustments for material non-cash activities, such as depreciation, amortization, change in fair value of warrants, and changes in working capital due to timing of product shipments (accounts receivable)...
2
[ "<tag1>", "The", "operating", "cash", "impact", "of", "this", "loss", "was", "$", "34,563,000", ",", "after", "adjusting", "for", "the", "recognition", "of", "non", "-", "cash", "development", "revenues", "of", "$", "1,817,000", ",", "the", "consideration", ...
[ "The", "operating", "cash", "impact", "of", "this", "loss", "was", "$", "34,563,000", ",", "after", "adjusting", "for", "the", "recognition", "of", "non", "-", "cash", "development", "revenues", "of", "$", "1,817,000", ",", "the", "consideration", "of", "non...
[ "The", "operating", "cash", "impact", "of", "this", "loss", "was", "$", "30,330,000", ",", "after", "adjusting", "for", "non", "-", "cash", "share", "-", "based", "compensation", ",", "other", "adjustments", "for", "material", "non", "-", "cash", "activities...
[]
[ "30,330,000" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, ...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, ...
1095981_15_item7_p41_s1
1095981_14_item7_p92_s0
See Notes to Consolidated Financial Statements included elsewhere herein for disclosure and discussion of stock-based compensation.
See Note 16 to the Consolidated Financial Statements included elsewhere herein for disclosure and discussion of share-based compensation.
2
[ "<tag1>", "See", "Notes", "to", "Consolidated", "Financial", "Statements", "included", "elsewhere", "herein", "for", "disclosure", "and", "discussion", "of", "stock", "-", "based", "compensation", ".", "<tag2>", "See", "Note", "16", "to", "the", "Consolidated", ...
[ "See", "Notes", "to", "Consolidated", "Financial", "Statements", "included", "elsewhere", "herein", "for", "disclosure", "and", "discussion", "of", "stock", "-", "based", "compensation", "." ]
[ "See", "Note", "16", "to", "the", "Consolidated", "Financial", "Statements", "included", "elsewhere", "herein", "for", "disclosure", "and", "discussion", "of", "share", "-", "based", "compensation", "." ]
[]
[ "Note", "16", "share" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, -100, 1, 1, -100, -100, 0, -100, -100, -100, 0, 0, -100, -100, 0, 0, -100, 1, 0, 0, 0, 0, -1 ]
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1 ]
1095981_15_item7_p42_s1
1095981_14_item7_p92_s0
See Notes to Consolidated Financial Statements included elsewhere herein for disclosure and discussion of stock-based compensation.
See Note 16 to the Consolidated Financial Statements included elsewhere herein for disclosure and discussion of share-based compensation.
2
[ "<tag1>", "See", "Notes", "to", "Consolidated", "Financial", "Statements", "included", "elsewhere", "herein", "for", "disclosure", "and", "discussion", "of", "stock", "-", "based", "compensation", ".", "<tag2>", "See", "Note", "16", "to", "the", "Consolidated", ...
[ "See", "Notes", "to", "Consolidated", "Financial", "Statements", "included", "elsewhere", "herein", "for", "disclosure", "and", "discussion", "of", "stock", "-", "based", "compensation", "." ]
[ "See", "Note", "16", "to", "the", "Consolidated", "Financial", "Statements", "included", "elsewhere", "herein", "for", "disclosure", "and", "discussion", "of", "share", "-", "based", "compensation", "." ]
[]
[ "Note", "16", "share" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, 0, 1, 1, -100, 0, -100, -100, -100, 0, -100, 0, -100, 0, -100, 0, -100, 1, 0, 0, -100, 0, -1 ]
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1 ]
1095981_16_item7_p43_s1
1095981_15_item7_p109_s0
See Note 2 to the Consolidated Financial Statements included elsewhere herein for disclosure and discussion of new accounting standards.
See Note 15 to the Consolidated Financial Statements included elsewhere herein for disclosure and discussion of share-based compensation.
2
[ "<tag1>", "See", "Note", "2", "to", "the", "Consolidated", "Financial", "Statements", "included", "elsewhere", "herein", "for", "disclosure", "and", "discussion", "of", "new", "accounting", "standards", ".", "<tag2>", "See", "Note", "15", "to", "the", "Consolida...
[ "See", "Note", "2", "to", "the", "Consolidated", "Financial", "Statements", "included", "elsewhere", "herein", "for", "disclosure", "and", "discussion", "of", "new", "accounting", "standards", "." ]
[ "See", "Note", "15", "to", "the", "Consolidated", "Financial", "Statements", "included", "elsewhere", "herein", "for", "disclosure", "and", "discussion", "of", "share", "-", "based", "compensation", "." ]
[]
[ "share", "based", "compensation" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, -100, -100, 0, 0, -100, -100, -100, 0, -100, -100, 0, 0, -100, 0, 0, -100, 1, 0, 1, 1, 0, -1 ]
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1 ]
1095981_16_item7_p14_s0
1095981_15_item7_p11_s5
The total award is intended to support all clinical, preclinical, regulatory, and technology development activities needed to complete the FDA approval process for use in thermal burn injury under a device-based PMA regulatory pathway.
The total award under the BARDA contract is intended to support all clinical, preclinical, regulatory, and technology development activities needed to complete the FDA approval process for use in thermal burn injury under a device-based PMA regulatory pathway.
2
[ "<tag1>", "The", "total", "award", "is", "intended", "to", "support", "all", "clinical", ",", "preclinical", ",", "regulatory", ",", "and", "technology", "development", "activities", "needed", "to", "complete", "the", "FDA", "approval", "process", "for", "use", ...
[ "The", "total", "award", "is", "intended", "to", "support", "all", "clinical", ",", "preclinical", ",", "regulatory", ",", "and", "technology", "development", "activities", "needed", "to", "complete", "the", "FDA", "approval", "process", "for", "use", "in", "t...
[ "The", "total", "award", "under", "the", "BARDA", "contract", "is", "intended", "to", "support", "all", "clinical", ",", "preclinical", ",", "regulatory", ",", "and", "technology", "development", "activities", "needed", "to", "complete", "the", "FDA", "approval"...
[]
[ "BARDA", "contract" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, ...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, ...
1095981_16_item7_p24_s0
1095981_15_item7_p21_s0
During the year ended December 31, 2014, we incurred $2,461,000 in qualified expenditures, and recognized a total of $2,645,000 in revenues, which included allowable fees as well as cost reimbursements.
During the year ended December 31, 2015, we incurred $6.3 million in BARDA qualified expenditures, and recognized a total of $6.8 million in BARDA revenues, which included allowable fees as well as cost reimbursements.
2
[ "<tag1>", "During", "the", "year", "ended", "December", "31", ",", "2014", ",", "we", "incurred", "$", "2,461,000", "in", "qualified", "expenditures", ",", "and", "recognized", "a", "total", "of", "$", "2,645,000", "in", "revenues", ",", "which", "included",...
[ "During", "the", "year", "ended", "December", "31", ",", "2014", ",", "we", "incurred", "$", "2,461,000", "in", "qualified", "expenditures", ",", "and", "recognized", "a", "total", "of", "$", "2,645,000", "in", "revenues", ",", "which", "included", "allowabl...
[ "During", "the", "year", "ended", "December", "31", ",", "2015", ",", "we", "incurred", "$", "6.3", "million", "in", "BARDA", "qualified", "expenditures", ",", "and", "recognized", "a", "total", "of", "$", "6.8", "million", "in", "BARDA", "revenues", ",", ...
[]
[ "6.3", "million", "BARDA", "6.8", "million", "BARDA" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, -100, ...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, ...
1095981_16_item7_p24_s1
1095981_15_item7_p21_s0
During the year ended December 31, 2014, we incurred $2,461,000 in qualified expenditures, and recognized a total of $2,645,000 in revenues, which included allowable fees as well as cost reimbursements.
During the year ended December 31, 2014, we incurred $2.5 million in BARDA qualified expenditures, and recognized a total of $2.6 million in BARDA revenues, which included allowable fees as well as cost reimbursements.
2
[ "<tag1>", "During", "the", "year", "ended", "December", "31", ",", "2014", ",", "we", "incurred", "$", "2,461,000", "in", "qualified", "expenditures", ",", "and", "recognized", "a", "total", "of", "$", "2,645,000", "in", "revenues", ",", "which", "included",...
[ "During", "the", "year", "ended", "December", "31", ",", "2014", ",", "we", "incurred", "$", "2,461,000", "in", "qualified", "expenditures", ",", "and", "recognized", "a", "total", "of", "$", "2,645,000", "in", "revenues", ",", "which", "included", "allowabl...
[ "During", "the", "year", "ended", "December", "31", ",", "2014", ",", "we", "incurred", "$", "2.5", "million", "in", "BARDA", "qualified", "expenditures", ",", "and", "recognized", "a", "total", "of", "$", "2.6", "million", "in", "BARDA", "revenues", ",", ...
[]
[ "2.5", "million", "BARDA", "2.6", "million", "BARDA" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, -100, ...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, ...
1095981_16_item7_p24_s2
1095981_15_item7_p21_s0
During the year ended December 31, 2014, we incurred $2,461,000 in qualified expenditures, and recognized a total of $2,645,000 in revenues, which included allowable fees as well as cost reimbursements.
During the year ended December 31, 2013, we incurred $3.0 million in BARDA qualified expenditures, and recognized a total of $3.3 million in BARDA revenues, which included allowable fees as well as cost reimbursements.
2
[ "<tag1>", "During", "the", "year", "ended", "December", "31", ",", "2014", ",", "we", "incurred", "$", "2,461,000", "in", "qualified", "expenditures", ",", "and", "recognized", "a", "total", "of", "$", "2,645,000", "in", "revenues", ",", "which", "included",...
[ "During", "the", "year", "ended", "December", "31", ",", "2014", ",", "we", "incurred", "$", "2,461,000", "in", "qualified", "expenditures", ",", "and", "recognized", "a", "total", "of", "$", "2,645,000", "in", "revenues", ",", "which", "included", "allowabl...
[ "During", "the", "year", "ended", "December", "31", ",", "2013", ",", "we", "incurred", "$", "3.0", "million", "in", "BARDA", "qualified", "expenditures", ",", "and", "recognized", "a", "total", "of", "$", "3.3", "million", "in", "BARDA", "revenues", ",", ...
[]
[ "3.0", "million", "BARDA", "3.3", "million", "BARDA" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, 0, 0, ...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, ...
1095981_16_item7_p24_s0
1095981_15_item7_p21_s1
During the year ended December 31, 2013, we incurred $3,053,000 in qualified expenditures, and recognized a total of $3,257,000 in revenues, which included allowable fees as well as cost reimbursements.
During the year ended December 31, 2015, we incurred $6.3 million in BARDA qualified expenditures, and recognized a total of $6.8 million in BARDA revenues, which included allowable fees as well as cost reimbursements.
2
[ "<tag1>", "During", "the", "year", "ended", "December", "31", ",", "2013", ",", "we", "incurred", "$", "3,053,000", "in", "qualified", "expenditures", ",", "and", "recognized", "a", "total", "of", "$", "3,257,000", "in", "revenues", ",", "which", "included",...
[ "During", "the", "year", "ended", "December", "31", ",", "2013", ",", "we", "incurred", "$", "3,053,000", "in", "qualified", "expenditures", ",", "and", "recognized", "a", "total", "of", "$", "3,257,000", "in", "revenues", ",", "which", "included", "allowabl...
[ "During", "the", "year", "ended", "December", "31", ",", "2015", ",", "we", "incurred", "$", "6.3", "million", "in", "BARDA", "qualified", "expenditures", ",", "and", "recognized", "a", "total", "of", "$", "6.8", "million", "in", "BARDA", "revenues", ",", ...
[]
[ "6.3", "million", "BARDA", "6.8", "million", "BARDA" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, -100, ...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, ...
1095981_16_item7_p24_s1
1095981_15_item7_p21_s1
During the year ended December 31, 2013, we incurred $3,053,000 in qualified expenditures, and recognized a total of $3,257,000 in revenues, which included allowable fees as well as cost reimbursements.
During the year ended December 31, 2014, we incurred $2.5 million in BARDA qualified expenditures, and recognized a total of $2.6 million in BARDA revenues, which included allowable fees as well as cost reimbursements.
2
[ "<tag1>", "During", "the", "year", "ended", "December", "31", ",", "2013", ",", "we", "incurred", "$", "3,053,000", "in", "qualified", "expenditures", ",", "and", "recognized", "a", "total", "of", "$", "3,257,000", "in", "revenues", ",", "which", "included",...
[ "During", "the", "year", "ended", "December", "31", ",", "2013", ",", "we", "incurred", "$", "3,053,000", "in", "qualified", "expenditures", ",", "and", "recognized", "a", "total", "of", "$", "3,257,000", "in", "revenues", ",", "which", "included", "allowabl...
[ "During", "the", "year", "ended", "December", "31", ",", "2014", ",", "we", "incurred", "$", "2.5", "million", "in", "BARDA", "qualified", "expenditures", ",", "and", "recognized", "a", "total", "of", "$", "2.6", "million", "in", "BARDA", "revenues", ",", ...
[]
[ "2.5", "million", "BARDA", "2.6", "million", "BARDA" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, 0, 0, ...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, ...
1095981_16_item7_p24_s2
1095981_15_item7_p21_s1
During the year ended December 31, 2013, we incurred $3,053,000 in qualified expenditures, and recognized a total of $3,257,000 in revenues, which included allowable fees as well as cost reimbursements.
During the year ended December 31, 2013, we incurred $3.0 million in BARDA qualified expenditures, and recognized a total of $3.3 million in BARDA revenues, which included allowable fees as well as cost reimbursements.
2
[ "<tag1>", "During", "the", "year", "ended", "December", "31", ",", "2013", ",", "we", "incurred", "$", "3,053,000", "in", "qualified", "expenditures", ",", "and", "recognized", "a", "total", "of", "$", "3,257,000", "in", "revenues", ",", "which", "included",...
[ "During", "the", "year", "ended", "December", "31", ",", "2013", ",", "we", "incurred", "$", "3,053,000", "in", "qualified", "expenditures", ",", "and", "recognized", "a", "total", "of", "$", "3,257,000", "in", "revenues", ",", "which", "included", "allowabl...
[ "During", "the", "year", "ended", "December", "31", ",", "2013", ",", "we", "incurred", "$", "3.0", "million", "in", "BARDA", "qualified", "expenditures", ",", "and", "recognized", "a", "total", "of", "$", "3.3", "million", "in", "BARDA", "revenues", ",", ...
[]
[ "3.0", "million", "BARDA", "3.3", "million", "BARDA" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, -100, ...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, ...
1095981_16_item7_p24_s0
1095981_15_item7_p21_s2
During the year ended December 31, 2012, we incurred $331,000 in qualified expenditures, and recognized a total of $355,000 in revenues, which included allowable fees as well as cost reimbursements.
During the year ended December 31, 2015, we incurred $6.3 million in BARDA qualified expenditures, and recognized a total of $6.8 million in BARDA revenues, which included allowable fees as well as cost reimbursements.
2
[ "<tag1>", "During", "the", "year", "ended", "December", "31", ",", "2012", ",", "we", "incurred", "$", "331,000", "in", "qualified", "expenditures", ",", "and", "recognized", "a", "total", "of", "$", "355,000", "in", "revenues", ",", "which", "included", "...
[ "During", "the", "year", "ended", "December", "31", ",", "2012", ",", "we", "incurred", "$", "331,000", "in", "qualified", "expenditures", ",", "and", "recognized", "a", "total", "of", "$", "355,000", "in", "revenues", ",", "which", "included", "allowable", ...
[ "During", "the", "year", "ended", "December", "31", ",", "2015", ",", "we", "incurred", "$", "6.3", "million", "in", "BARDA", "qualified", "expenditures", ",", "and", "recognized", "a", "total", "of", "$", "6.8", "million", "in", "BARDA", "revenues", ",", ...
[]
[ "6.3", "million", "BARDA", "6.8", "million", "BARDA" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, -100, ...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, ...
1095981_16_item7_p24_s1
1095981_15_item7_p21_s2
During the year ended December 31, 2012, we incurred $331,000 in qualified expenditures, and recognized a total of $355,000 in revenues, which included allowable fees as well as cost reimbursements.
During the year ended December 31, 2014, we incurred $2.5 million in BARDA qualified expenditures, and recognized a total of $2.6 million in BARDA revenues, which included allowable fees as well as cost reimbursements.
2
[ "<tag1>", "During", "the", "year", "ended", "December", "31", ",", "2012", ",", "we", "incurred", "$", "331,000", "in", "qualified", "expenditures", ",", "and", "recognized", "a", "total", "of", "$", "355,000", "in", "revenues", ",", "which", "included", "...
[ "During", "the", "year", "ended", "December", "31", ",", "2012", ",", "we", "incurred", "$", "331,000", "in", "qualified", "expenditures", ",", "and", "recognized", "a", "total", "of", "$", "355,000", "in", "revenues", ",", "which", "included", "allowable", ...
[ "During", "the", "year", "ended", "December", "31", ",", "2014", ",", "we", "incurred", "$", "2.5", "million", "in", "BARDA", "qualified", "expenditures", ",", "and", "recognized", "a", "total", "of", "$", "2.6", "million", "in", "BARDA", "revenues", ",", ...
[]
[ "2.5", "million", "BARDA", "2.6", "million", "BARDA" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, -100, ...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, ...
1095981_16_item7_p24_s2
1095981_15_item7_p21_s2
During the year ended December 31, 2012, we incurred $331,000 in qualified expenditures, and recognized a total of $355,000 in revenues, which included allowable fees as well as cost reimbursements.
During the year ended December 31, 2013, we incurred $3.0 million in BARDA qualified expenditures, and recognized a total of $3.3 million in BARDA revenues, which included allowable fees as well as cost reimbursements.
2
[ "<tag1>", "During", "the", "year", "ended", "December", "31", ",", "2012", ",", "we", "incurred", "$", "331,000", "in", "qualified", "expenditures", ",", "and", "recognized", "a", "total", "of", "$", "355,000", "in", "revenues", ",", "which", "included", "...
[ "During", "the", "year", "ended", "December", "31", ",", "2012", ",", "we", "incurred", "$", "331,000", "in", "qualified", "expenditures", ",", "and", "recognized", "a", "total", "of", "$", "355,000", "in", "revenues", ",", "which", "included", "allowable", ...
[ "During", "the", "year", "ended", "December", "31", ",", "2013", ",", "we", "incurred", "$", "3.0", "million", "in", "BARDA", "qualified", "expenditures", ",", "and", "recognized", "a", "total", "of", "$", "3.3", "million", "in", "BARDA", "revenues", ",", ...
[]
[ "3.0", "million", "BARDA", "3.3", "million", "BARDA" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, 0, 0, ...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, ...
1095981_16_item7_p25_s0
1095981_15_item7_p22_s0
We recognize deferred revenues, related party, as development revenue when certain performance obligations are met (i.e., using a proportional performance approach).
We recognize deferred revenues, related party, related to our relationships with Olympus and Senko, as development revenue when certain performance obligations are met (i.e., using a proportional performance approach).
2
[ "<tag1>", "We", "recognize", "deferred", "revenues", ",", "related", "party", ",", "as", "development", "revenue", "when", "certain", "performance", "obligations", "are", "met", "(", "i.e.", ",", "using", "a", "proportional", "performance", "approach", ")", ".",...
[ "We", "recognize", "deferred", "revenues", ",", "related", "party", ",", "as", "development", "revenue", "when", "certain", "performance", "obligations", "are", "met", "(", "i.e.", ",", "using", "a", "proportional", "performance", "approach", ")", "." ]
[ "We", "recognize", "deferred", "revenues", ",", "related", "party", ",", "related", "to", "our", "relationships", "with", "Olympus", "and", "Senko", ",", "as", "development", "revenue", "when", "certain", "performance", "obligations", "are", "met", "(", "i.e.", ...
[]
[ "relationships", "Olympus", "Senko" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, -100, -100, -100, 0, 0, -100, -100, 0, -100, -100, 0, 1, -100, ...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, ...
1095981_16_item7_p27_s1
1095981_15_item7_p24_s1
We expect approximately half of the work associated with Option 1, as amended, to be completed by the end of 2015.
We expect the work associated with Option 1, as amended, to be completed by the end of 2016 and overall contract revenues to remain materially consistent with 2015.
2
[ "<tag1>", "We", "expect", "approximately", "half", "of", "the", "work", "associated", "with", "Option", "1", ",", "as", "amended", ",", "to", "be", "completed", "by", "the", "end", "of", "2015", ".", "<tag2>", "We", "expect", "the", "work", "associated", ...
[ "We", "expect", "approximately", "half", "of", "the", "work", "associated", "with", "Option", "1", ",", "as", "amended", ",", "to", "be", "completed", "by", "the", "end", "of", "2015", "." ]
[ "We", "expect", "the", "work", "associated", "with", "Option", "1", ",", "as", "amended", ",", "to", "be", "completed", "by", "the", "end", "of", "2016", "and", "overall", "contract", "revenues", "to", "remain", "materially", "consistent", "with", "2015", ...
[]
[ "2016", "overall", "contract", "revenues", "remain", "materially", "consistent" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, 0, -100, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -100, 0, 0, 0, 0, 0, 0, 1, 0, 1...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1 ]
1095981_16_item7_p3_s0
1095981_15_item7_p3_s0
The primary therapeutic areas currently in the development pipeline are scleroderma, orthopedics, cardiovascular disease, specifically heart failure due to ischemic heart disease, and the treatment of thermal burns.
The primary therapeutic areas currently in the development pipeline are scleroderma, orthopedics, urinary incontinence, and the treatment of thermal burns.
2
[ "<tag1>", "The", "primary", "therapeutic", "areas", "currently", "in", "the", "development", "pipeline", "are", "scleroderma", ",", "orthopedics", ",", "cardiovascular", "disease", ",", "specifically", "heart", "failure", "due", "to", "ischemic", "heart", "disease",...
[ "The", "primary", "therapeutic", "areas", "currently", "in", "the", "development", "pipeline", "are", "scleroderma", ",", "orthopedics", ",", "cardiovascular", "disease", ",", "specifically", "heart", "failure", "due", "to", "ischemic", "heart", "disease", ",", "a...
[ "The", "primary", "therapeutic", "areas", "currently", "in", "the", "development", "pipeline", "are", "scleroderma", ",", "orthopedics", ",", "urinary", "incontinence", ",", "and", "the", "treatment", "of", "thermal", "burns", "." ]
[]
[ "urinary", "incontinence" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, -100, -100, -100, -100, -100, ...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1 ]
1095981_16_item7_p113_s0
1095981_15_item7_p41_s1
See Note 16 to the Consolidated Financial Statements included elsewhere herein for disclosure and discussion of share-based compensation.
See Note 2 to the Consolidated Financial Statements included elsewhere herein for disclosure and discussion of new accounting standards.
2
[ "<tag1>", "See", "Note", "16", "to", "the", "Consolidated", "Financial", "Statements", "included", "elsewhere", "herein", "for", "disclosure", "and", "discussion", "of", "share", "-", "based", "compensation", ".", "<tag2>", "See", "Note", "2", "to", "the", "Co...
[ "See", "Note", "16", "to", "the", "Consolidated", "Financial", "Statements", "included", "elsewhere", "herein", "for", "disclosure", "and", "discussion", "of", "share", "-", "based", "compensation", "." ]
[ "See", "Note", "2", "to", "the", "Consolidated", "Financial", "Statements", "included", "elsewhere", "herein", "for", "disclosure", "and", "discussion", "of", "new", "accounting", "standards", "." ]
[]
[ "new", "accounting", "standards" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, 0, -100, 0, 0, -100, -100, -100, 0, 0, 0, -100, 0, 0, -100, -100, -100, 1, 1, 1, 0, -1 ]
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1 ]
1095981_16_item7_p113_s0
1095981_15_item7_p42_s1
See Note 16 to the Consolidated Financial Statements included elsewhere herein for disclosure and discussion of share-based compensation.
See Note 2 to the Consolidated Financial Statements included elsewhere herein for disclosure and discussion of new accounting standards.
2
[ "<tag1>", "See", "Note", "16", "to", "the", "Consolidated", "Financial", "Statements", "included", "elsewhere", "herein", "for", "disclosure", "and", "discussion", "of", "share", "-", "based", "compensation", ".", "<tag2>", "See", "Note", "2", "to", "the", "Co...
[ "See", "Note", "16", "to", "the", "Consolidated", "Financial", "Statements", "included", "elsewhere", "herein", "for", "disclosure", "and", "discussion", "of", "share", "-", "based", "compensation", "." ]
[ "See", "Note", "2", "to", "the", "Consolidated", "Financial", "Statements", "included", "elsewhere", "herein", "for", "disclosure", "and", "discussion", "of", "new", "accounting", "standards", "." ]
[]
[ "new", "accounting", "standards" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, 0, -100, 0, 0, -100, 0, 0, 0, -100, -100, -100, 0, -100, 0, 0, -100, 1, 1, 1, -100, -1 ]
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1 ]
1095981_16_item7_p50_s0
1095981_15_item7_p44_s0
The following is a table summarizing the change in fair value of warrant liability for the years ended December 31, 2014, 2013 and 2012:
The following is a table summarizing the change in fair value of option liability for the years ended December 31, 2015, 2014 and 2013:
2
[ "<tag1>", "The", "following", "is", "a", "table", "summarizing", "the", "change", "in", "fair", "value", "of", "warrant", "liability", "for", "the", "years", "ended", "December", "31", ",", "2014", ",", "2013", "and", "2012", ":", "<tag2>", "The", "followi...
[ "The", "following", "is", "a", "table", "summarizing", "the", "change", "in", "fair", "value", "of", "warrant", "liability", "for", "the", "years", "ended", "December", "31", ",", "2014", ",", "2013", "and", "2012", ":" ]
[ "The", "following", "is", "a", "table", "summarizing", "the", "change", "in", "fair", "value", "of", "option", "liability", "for", "the", "years", "ended", "December", "31", ",", "2015", ",", "2014", "and", "2013", ":" ]
[]
[ "option" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, -100, -100, 0, -100, -100, -100, -100, -100, -100, -100, -100, -10...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1 ]
1095981_16_item7_p47_s0
1095981_15_item7_p47_s0
The following is a table summarizing the change in fair value of option liability for the years ended December 31, 2014, 2013 and 2012:
The following is a table summarizing the change in fair value of warrant liability for the years ended December 31, 2015, 2014 and 2013:
2
[ "<tag1>", "The", "following", "is", "a", "table", "summarizing", "the", "change", "in", "fair", "value", "of", "option", "liability", "for", "the", "years", "ended", "December", "31", ",", "2014", ",", "2013", "and", "2012", ":", "<tag2>", "The", "followin...
[ "The", "following", "is", "a", "table", "summarizing", "the", "change", "in", "fair", "value", "of", "option", "liability", "for", "the", "years", "ended", "December", "31", ",", "2014", ",", "2013", "and", "2012", ":" ]
[ "The", "following", "is", "a", "table", "summarizing", "the", "change", "in", "fair", "value", "of", "warrant", "liability", "for", "the", "years", "ended", "December", "31", ",", "2015", ",", "2014", "and", "2013", ":" ]
[]
[ "warrant" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, -100, -100, 0, -100, 0, -100, -100, -100, -100, -100, -100, 0, 1...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1 ]
1095981_16_item7_p58_s0
1095981_15_item7_p56_s0
Refer to Note 4 of the Notes to Consolidated Financial Statements for discussion of gain on previously held equity interest in joint venture.
Refer to Note 5 of the Notes to Consolidated Financial Statements for discussion of gain on Puregraft divestiture.
2
[ "<tag1>", "Refer", "to", "Note", "4", "of", "the", "Notes", "to", "Consolidated", "Financial", "Statements", "for", "discussion", "of", "gain", "on", "previously", "held", "equity", "interest", "in", "joint", "venture", ".", "<tag2>", "Refer", "to", "Note", ...
[ "Refer", "to", "Note", "4", "of", "the", "Notes", "to", "Consolidated", "Financial", "Statements", "for", "discussion", "of", "gain", "on", "previously", "held", "equity", "interest", "in", "joint", "venture", "." ]
[ "Refer", "to", "Note", "5", "of", "the", "Notes", "to", "Consolidated", "Financial", "Statements", "for", "discussion", "of", "gain", "on", "Puregraft", "divestiture", "." ]
[]
[ "Puregraft", "divestiture" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, -100, 0, -100, -100, -100, 0, 0, -100, -100, -100, -100, -100, -100, -100, 0, 0, ...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1 ]
1095981_16_item7_p77_s3
1095981_15_item7_p76_s0
As of December 31, 2014, 8,189 units had been converted into 15,747,000 shares of common stock.
As of December 31, 2015, all units had been converted into shares of common stock.
2
[ "<tag1>", "As", "of", "December", "31", ",", "2014", ",", "8,189", "units", "had", "been", "converted", "into", "15,747,000", "shares", "of", "common", "stock", ".", "<tag2>", "As", "of", "December", "31", ",", "2015", ",", "all", "units", "had", "been",...
[ "As", "of", "December", "31", ",", "2014", ",", "8,189", "units", "had", "been", "converted", "into", "15,747,000", "shares", "of", "common", "stock", "." ]
[ "As", "of", "December", "31", ",", "2015", ",", "all", "units", "had", "been", "converted", "into", "shares", "of", "common", "stock", "." ]
[]
[]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1 ]
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1 ]
1095981_16_item7_p78_s7
1095981_15_item7_p76_s0
As of December 31, 2014, 8,189 units had been converted into 15,747,000 shares of common stock.
As of December 31, 2015, all units had been converted into shares of common stock.
2
[ "<tag1>", "As", "of", "December", "31", ",", "2014", ",", "8,189", "units", "had", "been", "converted", "into", "15,747,000", "shares", "of", "common", "stock", ".", "<tag2>", "As", "of", "December", "31", ",", "2015", ",", "all", "units", "had", "been",...
[ "As", "of", "December", "31", ",", "2014", ",", "8,189", "units", "had", "been", "converted", "into", "15,747,000", "shares", "of", "common", "stock", "." ]
[ "As", "of", "December", "31", ",", "2015", ",", "all", "units", "had", "been", "converted", "into", "shares", "of", "common", "stock", "." ]
[]
[]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1 ]
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1 ]
1095981_16_item7_p82_s1
1095981_15_item7_p82_s1
The operating cash impact of this loss was $32,193,000, after adjusting for the recognition of development revenue of $381,000, and other non-cash development revenues of $5,411,000, the consideration of non-cash share-based compensation, other adjustments for material non-cash activities, such as depreciation, amortiz...
The operating cash impact of this loss was $20,468,000, after adjusting for non-cash share-based compensation, other adjustments for material non-cash activities, such as depreciation, amortization, change in fair value of warrants, and changes in working capital due to the timing of product shipments (accounts receiva...
2
[ "<tag1>", "The", "operating", "cash", "impact", "of", "this", "loss", "was", "$", "32,193,000", ",", "after", "adjusting", "for", "the", "recognition", "of", "development", "revenue", "of", "$", "381,000", ",", "and", "other", "non", "-", "cash", "developmen...
[ "The", "operating", "cash", "impact", "of", "this", "loss", "was", "$", "32,193,000", ",", "after", "adjusting", "for", "the", "recognition", "of", "development", "revenue", "of", "$", "381,000", ",", "and", "other", "non", "-", "cash", "development", "reven...
[ "The", "operating", "cash", "impact", "of", "this", "loss", "was", "$", "20,468,000", ",", "after", "adjusting", "for", "non", "-", "cash", "share", "-", "based", "compensation", ",", "other", "adjustments", "for", "material", "non", "-", "cash", "activities...
[]
[ "20,468,000" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, ...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, ...
1095981_16_item7_p83_s1
1095981_15_item7_p82_s1
The operating cash impact of this loss was $32,193,000, after adjusting for the recognition of development revenue of $381,000, and other non-cash development revenues of $5,411,000, the consideration of non-cash share-based compensation, other adjustments for material non-cash activities, such as depreciation, amortiz...
The operating cash impact of this loss was $30,330,000, after adjusting for non-cash share-based compensation, other adjustments for material non-cash activities, such as depreciation, amortization, change in fair value of warrants, and changes in working capital due to the timing of product shipments (accounts receiva...
2
[ "<tag1>", "The", "operating", "cash", "impact", "of", "this", "loss", "was", "$", "32,193,000", ",", "after", "adjusting", "for", "the", "recognition", "of", "development", "revenue", "of", "$", "381,000", ",", "and", "other", "non", "-", "cash", "developmen...
[ "The", "operating", "cash", "impact", "of", "this", "loss", "was", "$", "32,193,000", ",", "after", "adjusting", "for", "the", "recognition", "of", "development", "revenue", "of", "$", "381,000", ",", "and", "other", "non", "-", "cash", "development", "reven...
[ "The", "operating", "cash", "impact", "of", "this", "loss", "was", "$", "30,330,000", ",", "after", "adjusting", "for", "non", "-", "cash", "share", "-", "based", "compensation", ",", "other", "adjustments", "for", "material", "non", "-", "cash", "activities...
[]
[ "30,330,000" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, ...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, ...
1095981_16_item7_p85_s0
1095981_15_item7_p83_s0
Net cash used in investing activities for the year ended December 31, 2014 resulted in cash outflows for payment of a license termination fee of $400,000, expenditures for intellectual property of $255,000 and for purchases of property and equipment of $764,000 offset by proceeds from the sale of assets of $76,000.
Net cash used in investing activities for the year ended December 31, 2015 resulted in cash outflows for payment of expenditures for intellectual property of $13,000 and for purchases of property and equipment of $611,000.
2
[ "<tag1>", "Net", "cash", "used", "in", "investing", "activities", "for", "the", "year", "ended", "December", "31", ",", "2014", "resulted", "in", "cash", "outflows", "for", "payment", "of", "a", "license", "termination", "fee", "of", "$", "400,000", ",", "...
[ "Net", "cash", "used", "in", "investing", "activities", "for", "the", "year", "ended", "December", "31", ",", "2014", "resulted", "in", "cash", "outflows", "for", "payment", "of", "a", "license", "termination", "fee", "of", "$", "400,000", ",", "expenditures...
[ "Net", "cash", "used", "in", "investing", "activities", "for", "the", "year", "ended", "December", "31", ",", "2015", "resulted", "in", "cash", "outflows", "for", "payment", "of", "expenditures", "for", "intellectual", "property", "of", "$", "13,000", "and", ...
[]
[ "13,000", "611,000" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, ...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, ...
1095981_17_item7_p74_s0
1095981_16_item7_p108_s1
Under the revised guidance, entities have the option to first assess qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount as a basis for determining whether it is necessary to perform the two-step goodwill impairment test described ...
First we assess qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount as a basis for determining whether it is necessary to perform the two-step goodwill impairment test.
2
[ "<tag1>", "Under", "the", "revised", "guidance", ",", "entities", "have", "the", "option", "to", "first", "assess", "qualitative", "factors", "to", "determine", "whether", "it", "is", "more", "likely", "than", "not", "that", "the", "fair", "value", "of", "a"...
[ "Under", "the", "revised", "guidance", ",", "entities", "have", "the", "option", "to", "first", "assess", "qualitative", "factors", "to", "determine", "whether", "it", "is", "more", "likely", "than", "not", "that", "the", "fair", "value", "of", "a", "reporti...
[ "First", "we", "assess", "qualitative", "factors", "to", "determine", "whether", "it", "is", "more", "likely", "than", "not", "that", "the", "fair", "value", "of", "a", "reporting", "unit", "is", "less", "than", "its", "carrying", "amount", "as", "a", "bas...
[]
[ "First" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, ...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, ...
1095981_17_item7_p77_s0
1095981_16_item7_p110_s0
The estimated fair value of stock-based awards exchanged for employee and non-employee director services are expensed over the requisite service period and over the period during which the employee and non-employee director is required to provide service in exchange for the award.
Share-based compensation The estimated fair value of share-based awards exchanged for employee and non-employee director services are expensed over the requisite service period and over the period during which the employee and non-employee director is required to provide service in exchange for the award.
2
[ "<tag1>", "The", "estimated", "fair", "value", "of", "stock", "-", "based", "awards", "exchanged", "for", "employee", "and", "non", "-", "employee", "director", "services", "are", "expensed", "over", "the", "requisite", "service", "period", "and", "over", "the...
[ "The", "estimated", "fair", "value", "of", "stock", "-", "based", "awards", "exchanged", "for", "employee", "and", "non", "-", "employee", "director", "services", "are", "expensed", "over", "the", "requisite", "service", "period", "and", "over", "the", "period...
[ "Share", "-", "based", "compensation", "The", "estimated", "fair", "value", "of", "share", "-", "based", "awards", "exchanged", "for", "employee", "and", "non", "-", "employee", "director", "services", "are", "expensed", "over", "the", "requisite", "service", ...
[]
[ "Share", "compensation", "share" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, ...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, ...
1095981_17_item7_p78_s7
1095981_16_item7_p113_s0
See Note 2 to the Consolidated Financial Statements included elsewhere herein for disclosure and discussion of new accounting standards.
Recent Accounting Pronouncements See Note 2 to the Consolidated Financial Statements included elsewhere herein for disclosure and discussion of new accounting standards.
2
[ "<tag1>", "See", "Note", "2", "to", "the", "Consolidated", "Financial", "Statements", "included", "elsewhere", "herein", "for", "disclosure", "and", "discussion", "of", "new", "accounting", "standards", ".", "<tag2>", "Recent", "Accounting", "Pronouncements", "See",...
[ "See", "Note", "2", "to", "the", "Consolidated", "Financial", "Statements", "included", "elsewhere", "herein", "for", "disclosure", "and", "discussion", "of", "new", "accounting", "standards", "." ]
[ "Recent", "Accounting", "Pronouncements", "See", "Note", "2", "to", "the", "Consolidated", "Financial", "Statements", "included", "elsewhere", "herein", "for", "disclosure", "and", "discussion", "of", "new", "accounting", "standards", "." ]
[]
[ "Recent", "Accounting", "Pronouncements" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, 1, 1, 1, -100, -100, -100, -100, -100, 0, 0, -100, 0, -100, 0, 0, 0, 0, -100, -100, -100, -100, 0, 0...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1 ]
1095981_17_item7_p28_s10
1095981_16_item7_p14_s0
The total award under the BARDA contract is intended to support all clinical, preclinical, regulatory, and technology development activities needed to complete the FDA approval process for use in thermal burn injury under a device-based PMA regulatory pathway.
The total award under the BARDA contract is intended to support all clinical, preclinical, regulatory and technology development activities needed to complete the FDA approval process for use of DCCT-10 in thermal burn injury under a device-based PMA regulatory pathway and to provide preclinical data in burn complicate...
2
[ "<tag1>", "The", "total", "award", "under", "the", "BARDA", "contract", "is", "intended", "to", "support", "all", "clinical", ",", "preclinical", ",", "regulatory", ",", "and", "technology", "development", "activities", "needed", "to", "complete", "the", "FDA", ...
[ "The", "total", "award", "under", "the", "BARDA", "contract", "is", "intended", "to", "support", "all", "clinical", ",", "preclinical", ",", "regulatory", ",", "and", "technology", "development", "activities", "needed", "to", "complete", "the", "FDA", "approval"...
[ "The", "total", "award", "under", "the", "BARDA", "contract", "is", "intended", "to", "support", "all", "clinical", ",", "preclinical", ",", "regulatory", "and", "technology", "development", "activities", "needed", "to", "complete", "the", "FDA", "approval", "pr...
[]
[ "DCCT-10", "provide", "data", "complicated", "radiation", "exposure" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, ...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, ...
1095981_17_item7_p32_s0
1095981_16_item7_p19_s0
The future : We expect to continue to generate a majority of product revenues from the sale of Celution System devices and consumables to researchers, clinicians, and distributors in EMEA, Japan, Asia Pacific, and Americas.
The future: We expect to continue to generate a majority of product revenues from the sale of Cytori Cell Therapy-related products to researchers, clinicians, and distributors in EMEA, Japan, Asia Pacific, and the Americas.
2
[ "<tag1>", "The", "future", ":", "We", "expect", "to", "continue", "to", "generate", "a", "majority", "of", "product", "revenues", "from", "the", "sale", "of", "Celution", "System", "devices", "and", "consumables", "to", "researchers", ",", "clinicians", ",", ...
[ "The", "future", ":", "We", "expect", "to", "continue", "to", "generate", "a", "majority", "of", "product", "revenues", "from", "the", "sale", "of", "Celution", "System", "devices", "and", "consumables", "to", "researchers", ",", "clinicians", ",", "and", "d...
[ "The", "future", ":", "We", "expect", "to", "continue", "to", "generate", "a", "majority", "of", "product", "revenues", "from", "the", "sale", "of", "Cytori", "Cell", "Therapy", "-", "related", "products", "to", "researchers", ",", "clinicians", ",", "and", ...
[]
[ "Cytori", "Cell", "Therapy", "related", "products" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, ...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, ...
1095981_17_item7_p32_s1
1095981_16_item7_p19_s1
In Japan and EMEA, researchers will use the Celution System to construct ongoing and new investigator-initiated and funded studies focused on, but not limited to, hand scleroderma, Crohn disease, peripheral artery disease, erectile dysfunction, and diabetic foot ulcer.
In Japan and EMEA, researchers will use our technology in ongoing and new investigator-initiated and funded studies focused on, but not limited to, hand scleroderma, Crohn s disease, peripheral artery disease, erectile dysfunction, and diabetic foot ulcers.
2
[ "<tag1>", "In", "Japan", "and", "EMEA", ",", "researchers", "will", "use", "the", "Celution", "System", "to", "construct", "ongoing", "and", "new", "investigator", "-", "initiated", "and", "funded", "studies", "focused", "on", ",", "but", "not", "limited", "...
[ "In", "Japan", "and", "EMEA", ",", "researchers", "will", "use", "the", "Celution", "System", "to", "construct", "ongoing", "and", "new", "investigator", "-", "initiated", "and", "funded", "studies", "focused", "on", ",", "but", "not", "limited", "to", ",", ...
[ "In", "Japan", "and", "EMEA", ",", "researchers", "will", "use", "our", "technology", "in", "ongoing", "and", "new", "investigator", "-", "initiated", "and", "funded", "studies", "focused", "on", ",", "but", "not", "limited", "to", ",", "hand", "scleroderma"...
[]
[ "technology", "ulcers" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, ...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, ...
1095981_17_item7_p1_s2
1095981_16_item7_p1_s2
Cytori Cell Therapy can either be administered to the patient the same day or banked for future use.
Cytori Cell Therapy can either be administered to the patient the same day or cryopreserved for future use.
2
[ "<tag1>", "Cytori", "Cell", "Therapy", "can", "either", "be", "administered", "to", "the", "patient", "the", "same", "day", "or", "banked", "for", "future", "use", ".", "<tag2>", "Cytori", "Cell", "Therapy", "can", "either", "be", "administered", "to", "the"...
[ "Cytori", "Cell", "Therapy", "can", "either", "be", "administered", "to", "the", "patient", "the", "same", "day", "or", "banked", "for", "future", "use", "." ]
[ "Cytori", "Cell", "Therapy", "can", "either", "be", "administered", "to", "the", "patient", "the", "same", "day", "or", "cryopreserved", "for", "future", "use", "." ]
[]
[ "cryopreserved" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, -100, -100, -100, -100, -100, 0, -100, -100, -100, -100, 0, -100, -100, 0, 1, -100, -100, -100, -100, -1 ]
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1 ]
1095981_17_item7_p49_s2
1095981_16_item7_p42_s0
The following table summarizes the components of our stock-based compensation for the years ended December 31, 2015, 2014 and 2013:
The following table summarizes the components of our share-based compensation for the years ended December 31, 2016 and 2015 (in thousands):
2
[ "<tag1>", "The", "following", "table", "summarizes", "the", "components", "of", "our", "stock", "-", "based", "compensation", "for", "the", "years", "ended", "December", "31", ",", "2015", ",", "2014", "and", "2013", ":", "<tag2>", "The", "following", "table...
[ "The", "following", "table", "summarizes", "the", "components", "of", "our", "stock", "-", "based", "compensation", "for", "the", "years", "ended", "December", "31", ",", "2015", ",", "2014", "and", "2013", ":" ]
[ "The", "following", "table", "summarizes", "the", "components", "of", "our", "share", "-", "based", "compensation", "for", "the", "years", "ended", "December", "31", ",", "2016", "and", "2015", "(", "in", "thousands", "):" ]
[]
[ "share", "thousands", "):" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, -100, -100, 0, -100, -100, -100, -100, -100, 1, -100, -100, -100, 0, 0, 0, ...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1 ]
1095981_17_item7_p78_s7
1095981_16_item7_p43_s1
See Note 15 to the Consolidated Financial Statements included elsewhere herein for disclosure and discussion of share-based compensation.
Recent Accounting Pronouncements See Note 2 to the Consolidated Financial Statements included elsewhere herein for disclosure and discussion of new accounting standards.
2
[ "<tag1>", "See", "Note", "15", "to", "the", "Consolidated", "Financial", "Statements", "included", "elsewhere", "herein", "for", "disclosure", "and", "discussion", "of", "share", "-", "based", "compensation", ".", "<tag2>", "Recent", "Accounting", "Pronouncements", ...
[ "See", "Note", "15", "to", "the", "Consolidated", "Financial", "Statements", "included", "elsewhere", "herein", "for", "disclosure", "and", "discussion", "of", "share", "-", "based", "compensation", "." ]
[ "Recent", "Accounting", "Pronouncements", "See", "Note", "2", "to", "the", "Consolidated", "Financial", "Statements", "included", "elsewhere", "herein", "for", "disclosure", "and", "discussion", "of", "new", "accounting", "standards", "." ]
[]
[ "Recent", "Accounting", "Pronouncements", "new", "accounting", "standards" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, 1, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 1, 1, 0, -1 ]
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1 ]
1095981_17_item7_p7_s2
1095981_16_item7_p4_s2
The trial evaluates the safety and efficacy of a single administration of Cytori Cell Therapy in scleroderma patients affecting the hands and fingers.
The trial evaluates the safety and efficacy of a single administration of Habeo Cell Therapy in patients with scleroderma affecting the hands and fingers.
2
[ "<tag1>", "The", "trial", "evaluates", "the", "safety", "and", "efficacy", "of", "a", "single", "administration", "of", "Cytori", "Cell", "Therapy", "in", "scleroderma", "patients", "affecting", "the", "hands", "and", "fingers", ".", "<tag2>", "The", "trial", ...
[ "The", "trial", "evaluates", "the", "safety", "and", "efficacy", "of", "a", "single", "administration", "of", "Cytori", "Cell", "Therapy", "in", "scleroderma", "patients", "affecting", "the", "hands", "and", "fingers", "." ]
[ "The", "trial", "evaluates", "the", "safety", "and", "efficacy", "of", "a", "single", "administration", "of", "Habeo", "Cell", "Therapy", "in", "patients", "with", "scleroderma", "affecting", "the", "hands", "and", "fingers", "." ]
[]
[ "Habeo" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, -100, -100, 0, -100, -100, -100, -100, -100, -100, -100, -100, -100, 1, -100, -100, ...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1 ]
1095981_17_item7_p51_s3
1095981_16_item7_p50_s0
The following is a table summarizing the change in fair value of option liability for the years ended December 31, 2015, 2014 and 2013:
Change in fair value of warrant liability The following is a table summarizing the change in fair value of warrant liability for the years ended December 31, 2016 and 2015:
2
[ "<tag1>", "The", "following", "is", "a", "table", "summarizing", "the", "change", "in", "fair", "value", "of", "option", "liability", "for", "the", "years", "ended", "December", "31", ",", "2015", ",", "2014", "and", "2013", ":", "<tag2>", "Change", "in", ...
[ "The", "following", "is", "a", "table", "summarizing", "the", "change", "in", "fair", "value", "of", "option", "liability", "for", "the", "years", "ended", "December", "31", ",", "2015", ",", "2014", "and", "2013", ":" ]
[ "Change", "in", "fair", "value", "of", "warrant", "liability", "The", "following", "is", "a", "table", "summarizing", "the", "change", "in", "fair", "value", "of", "warrant", "liability", "for", "the", "years", "ended", "December", "31", ",", "2016", "and", ...
[]
[ "Change", "warrant", "warrant" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, 1, 0, 0, 0, -100, 1, -100, 0, 0, -100, 0, -100, 0, -100, 0, ...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1 ]
1095981_17_item7_p59_s4
1095981_16_item7_p64_s1
We have had, and we will likely continue to have, an ongoing need to raise additional cash from outside sources to fund our future operations.
We have had, and we will likely continue to have, an ongoing need to raise additional cash from outside sources to fund our future clinical development programs and other operations.
2
[ "<tag1>", "We", "have", "had", ",", "and", "we", "will", "likely", "continue", "to", "have", ",", "an", "ongoing", "need", "to", "raise", "additional", "cash", "from", "outside", "sources", "to", "fund", "our", "future", "operations", ".", "<tag2>", "We", ...
[ "We", "have", "had", ",", "and", "we", "will", "likely", "continue", "to", "have", ",", "an", "ongoing", "need", "to", "raise", "additional", "cash", "from", "outside", "sources", "to", "fund", "our", "future", "operations", "." ]
[ "We", "have", "had", ",", "and", "we", "will", "likely", "continue", "to", "have", ",", "an", "ongoing", "need", "to", "raise", "additional", "cash", "from", "outside", "sources", "to", "fund", "our", "future", "clinical", "development", "programs", "and", ...
[]
[ "clinical", "development", "programs" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, -100, -100, 0, -100, -100, 0, 0, 0, -100, -100, -100, -100...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, ...
1095981_17_item7_p64_s4
1095981_16_item7_p88_s0
The net cash provided by financing activities for the year ended December 31, 2015 related primarily to a sale of common stock.
The net cash provided by financing activities for the year ended December 31, 2016 related primarily to a sale of common stock through our Rights Offering and ATM offering program.
2
[ "<tag1>", "The", "net", "cash", "provided", "by", "financing", "activities", "for", "the", "year", "ended", "December", "31", ",", "2015", "related", "primarily", "to", "a", "sale", "of", "common", "stock", ".", "<tag2>", "The", "net", "cash", "provided", ...
[ "The", "net", "cash", "provided", "by", "financing", "activities", "for", "the", "year", "ended", "December", "31", ",", "2015", "related", "primarily", "to", "a", "sale", "of", "common", "stock", "." ]
[ "The", "net", "cash", "provided", "by", "financing", "activities", "for", "the", "year", "ended", "December", "31", ",", "2016", "related", "primarily", "to", "a", "sale", "of", "common", "stock", "through", "our", "Rights", "Offering", "and", "ATM", "offeri...
[]
[ "Rights", "Offering", "ATM", "offering", "program" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, 0, 0, 0, 0, -100, 0, 0, -100, -100, -100, -100, 0, -100, -100, -100, 0, -100, ...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1 ]
1095981_18_item7_p13_s0
1095981_17_item7_p37_s0
The future: We expect to continue to see variation in our gross profit margin as the product mix, distributor and direct sales mix and geographic mix comprising revenues fluctuate.
The futur e: We expect to continue to see variation in our gross profit margin as the product mix, distributor and direct sales mix and geographic mix comprising revenues fluctuate.
2
[ "<tag1>", "The", "future", ":", "We", "expect", "to", "continue", "to", "see", "variation", "in", "our", "gross", "profit", "margin", "as", "the", "product", "mix", ",", "distributor", "and", "direct", "sales", "mix", "and", "geographic", "mix", "comprising"...
[ "The", "future", ":", "We", "expect", "to", "continue", "to", "see", "variation", "in", "our", "gross", "profit", "margin", "as", "the", "product", "mix", ",", "distributor", "and", "direct", "sales", "mix", "and", "geographic", "mix", "comprising", "revenue...
[ "The", "futur", "e", ":", "We", "expect", "to", "continue", "to", "see", "variation", "in", "our", "gross", "profit", "margin", "as", "the", "product", "mix", ",", "distributor", "and", "direct", "sales", "mix", "and", "geographic", "mix", "comprising", "r...
[]
[ "futur", "e" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, -100, 1, 1, -100, 0, -100, 0, 0, ...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, ...
1095981_18_item7_p13_s1
1095981_17_item7_p37_s1
We are investigating various pricing options for our cellular therapeutics, including orphan pricing for our Habeo Cell Therapy, which may help to increase our gross profit margins in 2017 and beyond.
We are investigating various pricing options for our cellular therapeutics, which ma y help to increase our gross profit margins in 2018 and beyond.
2
[ "<tag1>", "We", "are", "investigating", "various", "pricing", "options", "for", "our", "cellular", "therapeutics", ",", "including", "orphan", "pricing", "for", "our", "Habeo", "Cell", "Therapy", ",", "which", "may", "help", "to", "increase", "our", "gross", "...
[ "We", "are", "investigating", "various", "pricing", "options", "for", "our", "cellular", "therapeutics", ",", "including", "orphan", "pricing", "for", "our", "Habeo", "Cell", "Therapy", ",", "which", "may", "help", "to", "increase", "our", "gross", "profit", "...
[ "We", "are", "investigating", "various", "pricing", "options", "for", "our", "cellular", "therapeutics", ",", "which", "ma", "y", "help", "to", "increase", "our", "gross", "profit", "margins", "in", "2018", "and", "beyond", "." ]
[]
[]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, -100, -100, -100, -100, ...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1 ]
1095981_18_item7_p16_s1
1095981_17_item7_p40_s0
The following table summarizes the components of our research and development expenses for the years ended December 31, 2016 and 2015 (in thousands):
The following table summarizes the components of our sales and marketing expenses for the years ended December 31, 2017 and 2016 (in thousands):
2
[ "<tag1>", "The", "following", "table", "summarizes", "the", "components", "of", "our", "research", "and", "development", "expenses", "for", "the", "years", "ended", "December", "31", ",", "2016", "and", "2015", "(", "in", "thousands", "):", "<tag2>", "The", ...
[ "The", "following", "table", "summarizes", "the", "components", "of", "our", "research", "and", "development", "expenses", "for", "the", "years", "ended", "December", "31", ",", "2016", "and", "2015", "(", "in", "thousands", "):" ]
[ "The", "following", "table", "summarizes", "the", "components", "of", "our", "sales", "and", "marketing", "expenses", "for", "the", "years", "ended", "December", "31", ",", "2017", "and", "2016", "(", "in", "thousands", "):" ]
[]
[ "sales", "marketing" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, -100, -100, -100, 0, -100, -100, -100, 0, 1, -100, 1, -100, -100, 0, ...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1 ]
1095981_18_item7_p22_s2
1095981_17_item7_p40_s0
The following table summarizes the components of our research and development expenses for the years ended December 31, 2016 and 2015 (in thousands):
The following table summarizes the components of our share-based compensation expenses for the years ended December 31, 2017 and 2016 (in thousands):
2
[ "<tag1>", "The", "following", "table", "summarizes", "the", "components", "of", "our", "research", "and", "development", "expenses", "for", "the", "years", "ended", "December", "31", ",", "2016", "and", "2015", "(", "in", "thousands", "):", "<tag2>", "The", ...
[ "The", "following", "table", "summarizes", "the", "components", "of", "our", "research", "and", "development", "expenses", "for", "the", "years", "ended", "December", "31", ",", "2016", "and", "2015", "(", "in", "thousands", "):" ]
[ "The", "following", "table", "summarizes", "the", "components", "of", "our", "share", "-", "based", "compensation", "expenses", "for", "the", "years", "ended", "December", "31", ",", "2017", "and", "2016", "(", "in", "thousands", "):" ]
[]
[ "share", "based", "compensation" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, -100, -100, 0, 0, -100, -100, 0, 0, 1, -100, 1, 1, -100, -100, 0, ...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1 ]
1095981_18_item7_p14_s2
1095981_17_item7_p42_s1
The following table summarizes the components of our sales and marketing expenses for the years ended December 31, 2016 and 2015 (in thousands):
The following table summarizes the components of our research and development expenses for the years ended December 31, 2017 and 2016 (in thousands):
2
[ "<tag1>", "The", "following", "table", "summarizes", "the", "components", "of", "our", "sales", "and", "marketing", "expenses", "for", "the", "years", "ended", "December", "31", ",", "2016", "and", "2015", "(", "in", "thousands", "):", "<tag2>", "The", "foll...
[ "The", "following", "table", "summarizes", "the", "components", "of", "our", "sales", "and", "marketing", "expenses", "for", "the", "years", "ended", "December", "31", ",", "2016", "and", "2015", "(", "in", "thousands", "):" ]
[ "The", "following", "table", "summarizes", "the", "components", "of", "our", "research", "and", "development", "expenses", "for", "the", "years", "ended", "December", "31", ",", "2017", "and", "2016", "(", "in", "thousands", "):" ]
[]
[ "research", "development" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, -100, -100, -100, -100, -100, -100, 0, 0, 1, -100, 1, -100, -100, -100...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1 ]
1095981_18_item7_p22_s2
1095981_17_item7_p42_s1
The following table summarizes the components of our sales and marketing expenses for the years ended December 31, 2016 and 2015 (in thousands):
The following table summarizes the components of our share-based compensation expenses for the years ended December 31, 2017 and 2016 (in thousands):
2
[ "<tag1>", "The", "following", "table", "summarizes", "the", "components", "of", "our", "sales", "and", "marketing", "expenses", "for", "the", "years", "ended", "December", "31", ",", "2016", "and", "2015", "(", "in", "thousands", "):", "<tag2>", "The", "foll...
[ "The", "following", "table", "summarizes", "the", "components", "of", "our", "sales", "and", "marketing", "expenses", "for", "the", "years", "ended", "December", "31", ",", "2016", "and", "2015", "(", "in", "thousands", "):" ]
[ "The", "following", "table", "summarizes", "the", "components", "of", "our", "share", "-", "based", "compensation", "expenses", "for", "the", "years", "ended", "December", "31", ",", "2017", "and", "2016", "(", "in", "thousands", "):" ]
[]
[ "share", "based", "compensation" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, 0, -100, -100, -100, -100, -100, -100, -100, 1, -100, 1, 1, 0, 0, -1...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1 ]
1095981_18_item7_p26_s0
1095981_17_item7_p53_s0
Financing items The following table summarizes loss on debt extinguishment, interest income, interest expense, and other income and expense for the years ended December 31, 2016 and 2015 (in thousands):
Financing items The following table summarizes interest income, interest expense, and other income and expense for the years ended December 31, 2017 and 2016 (in thousands):
2
[ "<tag1>", "Financing", "items", "The", "following", "table", "summarizes", "loss", "on", "debt", "extinguishment", ",", "interest", "income", ",", "interest", "expense", ",", "and", "other", "income", "and", "expense", "for", "the", "years", "ended", "December",...
[ "Financing", "items", "The", "following", "table", "summarizes", "loss", "on", "debt", "extinguishment", ",", "interest", "income", ",", "interest", "expense", ",", "and", "other", "income", "and", "expense", "for", "the", "years", "ended", "December", "31", "...
[ "Financing", "items", "The", "following", "table", "summarizes", "interest", "income", ",", "interest", "expense", ",", "and", "other", "income", "and", "expense", "for", "the", "years", "ended", "December", "31", ",", "2017", "and", "2016", "(", "in", "thou...
[]
[]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, -100, -100, ...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, ...
1095981_18_item7_p30_s1
1095981_17_item7_p59_s1
We have an accumulated deficit of $379.1 million as of December 31, 2016.
We have an accumulated deficit of $401.7 million as of December 31, 2017.
2
[ "<tag1>", "We", "have", "an", "accumulated", "deficit", "of", "$", "379.1", "million", "as", "of", "December", "31", ",", "2016", ".", "<tag2>", "We", "have", "an", "accumulated", "deficit", "of", "$", "401.7", "million", "as", "of", "December", "31", ",...
[ "We", "have", "an", "accumulated", "deficit", "of", "$", "379.1", "million", "as", "of", "December", "31", ",", "2016", "." ]
[ "We", "have", "an", "accumulated", "deficit", "of", "$", "401.7", "million", "as", "of", "December", "31", ",", "2017", "." ]
[]
[ "401.7" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, -100, 0, -100, -100, -100, -100, -100, 1, -100, -100, -100, 0, -100, 0, -100, -100, -1 ]
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1 ]
1095981_18_item7_p32_s3
1095981_17_item7_p60_s1
Although sa les of our common stock have taken place pursuant to our ATM offering program, there can be no assurance that we will be successful in consummating future sales based on prevailing market conditions or in the quantities or at the prices that we deem approp riate.
Although sales of our common stock have taken place pursuant to our ATM offering program, there can be no assurance that we will be successful in consummating future sales based on prevailing market conditions or in the quantities or at the prices that we deem appropriate.
2
[ "<tag1>", "Although", "sa", "les", "of", "our", "common", "stock", "have", "taken", "place", "pursuant", "to", "our", "ATM", "offering", "program", ",", "there", "can", "be", "no", "assurance", "that", "we", "will", "be", "successful", "in", "consummating", ...
[ "Although", "sa", "les", "of", "our", "common", "stock", "have", "taken", "place", "pursuant", "to", "our", "ATM", "offering", "program", ",", "there", "can", "be", "no", "assurance", "that", "we", "will", "be", "successful", "in", "consummating", "future", ...
[ "Although", "sales", "of", "our", "common", "stock", "have", "taken", "place", "pursuant", "to", "our", "ATM", "offering", "program", ",", "there", "can", "be", "no", "assurance", "that", "we", "will", "be", "successful", "in", "consummating", "future", "sal...
[]
[ "appropriate" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, ...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, ...
1095981_18_item7_p32_s5
1095981_17_item7_p60_s3
As of December 31, 2016, our public float was 21.5 million shares, the valu e of which was $32.5 million based upon the closing price of our common stock of $1.51 on such date.
As of December 31, 2017, our public float was 57.8 million shares, the value of which was $17.3 million based upon the closing price of our common stock of $0.30 on such date.
2
[ "<tag1>", "As", "of", "December", "31", ",", "2016", ",", "our", "public", "float", "was", "21.5", "million", "shares", ",", "the", "valu", "e", "of", "which", "was", "$", "32.5", "million", "based", "upon", "the", "closing", "price", "of", "our", "com...
[ "As", "of", "December", "31", ",", "2016", ",", "our", "public", "float", "was", "21.5", "million", "shares", ",", "the", "valu", "e", "of", "which", "was", "$", "32.5", "million", "based", "upon", "the", "closing", "price", "of", "our", "common", "sto...
[ "As", "of", "December", "31", ",", "2017", ",", "our", "public", "float", "was", "57.8", "million", "shares", ",", "the", "value", "of", "which", "was", "$", "17.3", "million", "based", "upon", "the", "closing", "price", "of", "our", "common", "stock", ...
[]
[ "57.8", "value", "17.3", "0.30" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, ...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, ...
1095981_18_item7_p35_s2
1095981_17_item7_p62_s5
Pursuant to these securities transactions and related equity issuances, as well as anticipated gross profits and potential outside sources of capital, we believe we have sufficient cash to fund operations through at least through Q2 2017.
Pursuant to these securities transactions and related equity issuances, as well as anticipated gross profits and potential outside sources of capital, we believe we have sufficient cash to fund operations through at least through the third quarter of 2018.
2
[ "<tag1>", "Pursuant", "to", "these", "securities", "transactions", "and", "related", "equity", "issuances", ",", "as", "well", "as", "anticipated", "gross", "profits", "and", "potential", "outside", "sources", "of", "capital", ",", "we", "believe", "we", "have",...
[ "Pursuant", "to", "these", "securities", "transactions", "and", "related", "equity", "issuances", ",", "as", "well", "as", "anticipated", "gross", "profits", "and", "potential", "outside", "sources", "of", "capital", ",", "we", "believe", "we", "have", "sufficie...
[ "Pursuant", "to", "these", "securities", "transactions", "and", "related", "equity", "issuances", ",", "as", "well", "as", "anticipated", "gross", "profits", "and", "potential", "outside", "sources", "of", "capital", ",", "we", "believe", "we", "have", "sufficie...
[]
[ "third", "quarter" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, ...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, ...
1096376_12_item7_p27_s5
1096376_11_item7_p26_s5
The abandonment provided an income tax deduction for the entire original $14.3 million tax basis investment in Zero Water and reduced income tax payments by approximately $5.0 million.
The increase in the effective tax rate was primarily the result of the abandonment of our investment in Zero Water in 2009 which provided an income tax deduction for the entire original $14.3 million tax basis investment in Zero Water and reduced 2009 income tax payments by approximately $5.0 million.
2
[ "<tag1>", "The", "abandonment", "provided", "an", "income", "tax", "deduction", "for", "the", "entire", "original", "$", "14.3", "million", "tax", "basis", "investment", "in", "Zero", "Water", "and", "reduced", "income", "tax", "payments", "by", "approximately",...
[ "The", "abandonment", "provided", "an", "income", "tax", "deduction", "for", "the", "entire", "original", "$", "14.3", "million", "tax", "basis", "investment", "in", "Zero", "Water", "and", "reduced", "income", "tax", "payments", "by", "approximately", "$", "5...
[ "The", "increase", "in", "the", "effective", "tax", "rate", "was", "primarily", "the", "result", "of", "the", "abandonment", "of", "our", "investment", "in", "Zero", "Water", "in", "2009", "which", "provided", "an", "income", "tax", "deduction", "for", "the"...
[]
[ "increase", "effective", "rate", "primarily", "result", "2009" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, 0, 1, -100, -100, 1, -100, 1, 0, 1, 0,...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, ...
1096376_12_item7_p31_s0
1096376_11_item7_p30_s1
We are subject to 0.15% per annum unused fee payable quarterly.
We are subject to an unused fee payable quarterly.
2
[ "<tag1>", "We", "are", "subject", "to", "0.15", "%", "per", "annum", "unused", "fee", "payable", "quarterly", ".", "<tag2>", "We", "are", "subject", "to", "an", "unused", "fee", "payable", "quarterly", ".", "<tag3>" ]
[ "We", "are", "subject", "to", "0.15", "%", "per", "annum", "unused", "fee", "payable", "quarterly", "." ]
[ "We", "are", "subject", "to", "an", "unused", "fee", "payable", "quarterly", "." ]
[]
[]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1 ]
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1 ]
1096376_12_item7_p5_s1
1096376_11_item7_p3_s1
We believe these factors have primarily driven the decline in the number of new customer starts during 2008, 2009 and 2010.
We believe these factors have primarily driven the decline in the number of new customer starts which in turn began to hamper reactivation revenue.
2
[ "<tag1>", "We", "believe", "these", "factors", "have", "primarily", "driven", "the", "decline", "in", "the", "number", "of", "new", "customer", "starts", "during", "2008", ",", "2009", "and", "2010", ".", "<tag2>", "We", "believe", "these", "factors", "have"...
[ "We", "believe", "these", "factors", "have", "primarily", "driven", "the", "decline", "in", "the", "number", "of", "new", "customer", "starts", "during", "2008", ",", "2009", "and", "2010", "." ]
[ "We", "believe", "these", "factors", "have", "primarily", "driven", "the", "decline", "in", "the", "number", "of", "new", "customer", "starts", "which", "in", "turn", "began", "to", "hamper", "reactivation", "revenue", "." ]
[]
[ "turn", "began", "hamper", "reactivation", "revenue" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, -100, 0, -100, 0, -100, 0, 0, 0, 0, 0, 0, -100, 0, -100, 0, 0, 0, 0, 1, 1, 0, ...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1 ]
1096376_12_item7_p6_s2
1096376_11_item7_p3_s3
We are continuing to see a challenging environment develop in 2011 as we experienced significantly reduced sales below the comparable 2010 period throughout the month of January.
We experienced significantly reduced sales below the comparable 2010 period throughout the month of January.
2
[ "<tag1>", "We", "are", "continuing", "to", "see", "a", "challenging", "environment", "develop", "in", "2011", "as", "we", "experienced", "significantly", "reduced", "sales", "below", "the", "comparable", "2010", "period", "throughout", "the", "month", "of", "Jan...
[ "We", "are", "continuing", "to", "see", "a", "challenging", "environment", "develop", "in", "2011", "as", "we", "experienced", "significantly", "reduced", "sales", "below", "the", "comparable", "2010", "period", "throughout", "the", "month", "of", "January", "."...
[ "We", "experienced", "significantly", "reduced", "sales", "below", "the", "comparable", "2010", "period", "throughout", "the", "month", "of", "January", "." ]
[]
[]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, ...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1 ]
1096376_13_item7_p10_s0
1096376_12_item7_p13_s0
Deferred tax assets are evaluated for future realization and reduced by a valuation allowance to the extent we believe a portion will not be realized.
realization and reduced by a valuation allowance to the extent we believe a portion will not be realized.
2
[ "<tag1>", "Deferred", "tax", "assets", "are", "evaluated", "for", "future", "realization", "and", "reduced", "by", "a", "valuation", "allowance", "to", "the", "extent", "we", "believe", "a", "portion", "will", "not", "be", "realized", ".", "<tag2>", "realizati...
[ "Deferred", "tax", "assets", "are", "evaluated", "for", "future", "realization", "and", "reduced", "by", "a", "valuation", "allowance", "to", "the", "extent", "we", "believe", "a", "portion", "will", "not", "be", "realized", "." ]
[ "realization", "and", "reduced", "by", "a", "valuation", "allowance", "to", "the", "extent", "we", "believe", "a", "portion", "will", "not", "be", "realized", "." ]
[]
[]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, ...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1 ]
1096376_13_item7_p12_s3
1096376_12_item7_p18_s2
Accordingly, the operating results of these discontinued operations have been presented separately from continuing operations for all periods presented.
Accordingly, the operating results of NuKitchen have been presented separately from continuing operations for all periods presented.
2
[ "<tag1>", "Accordingly", ",", "the", "operating", "results", "of", "these", "discontinued", "operations", "have", "been", "presented", "separately", "from", "continuing", "operations", "for", "all", "periods", "presented", ".", "<tag2>", "Accordingly", ",", "the", ...
[ "Accordingly", ",", "the", "operating", "results", "of", "these", "discontinued", "operations", "have", "been", "presented", "separately", "from", "continuing", "operations", "for", "all", "periods", "presented", "." ]
[ "Accordingly", ",", "the", "operating", "results", "of", "NuKitchen", "have", "been", "presented", "separately", "from", "continuing", "operations", "for", "all", "periods", "presented", "." ]
[]
[ "NuKitchen" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, -100, -100, -100, -100, -100, -100, 1, -100, -100, 0, -100, -100, -100, -100, -100, -100, 0, -100, 0...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1 ]
1096376_13_item7_p1_s1
1096376_12_item7_p1_s1
The Nutrisystem programs are based on 40 years of nutrition research and on the science of the low Glycemic Index.
Our programs are based on 40 years of nutrition research and on the science of the low Glycemic Index.
2
[ "<tag1>", "The", "Nutrisystem", "programs", "are", "based", "on", "40", "years", "of", "nutrition", "research", "and", "on", "the", "science", "of", "the", "low", "Glycemic", "Index", ".", "<tag2>", "Our", "programs", "are", "based", "on", "40", "years", "...
[ "The", "Nutrisystem", "programs", "are", "based", "on", "40", "years", "of", "nutrition", "research", "and", "on", "the", "science", "of", "the", "low", "Glycemic", "Index", "." ]
[ "Our", "programs", "are", "based", "on", "40", "years", "of", "nutrition", "research", "and", "on", "the", "science", "of", "the", "low", "Glycemic", "Index", "." ]
[]
[]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, ...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1 ]
1096376_13_item7_p22_s7
1096376_12_item7_p28_s8
We anticipate that we will meet all annual purchase obligations.
We anticipate that we will meet all annual purchase and space obligations.
2
[ "<tag1>", "We", "anticipate", "that", "we", "will", "meet", "all", "annual", "purchase", "obligations", ".", "<tag2>", "We", "anticipate", "that", "we", "will", "meet", "all", "annual", "purchase", "and", "space", "obligations", ".", "<tag3>" ]
[ "We", "anticipate", "that", "we", "will", "meet", "all", "annual", "purchase", "obligations", "." ]
[ "We", "anticipate", "that", "we", "will", "meet", "all", "annual", "purchase", "and", "space", "obligations", "." ]
[]
[ "space" ]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, -100, -100, -100, 0, 0, -100, -100, -100, 0, -100, 1, -100, -100, -1 ]
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1 ]
1096376_13_item7_p3_s6
1096376_12_item7_p5_s1
We believe these factors have primarily driven the decline in the number of new customer starts which in turn began to hamper reactivation revenue.
We believe these factors have primarily driven the decline in the number of new customer starts.
2
[ "<tag1>", "We", "believe", "these", "factors", "have", "primarily", "driven", "the", "decline", "in", "the", "number", "of", "new", "customer", "starts", "which", "in", "turn", "began", "to", "hamper", "reactivation", "revenue", ".", "<tag2>", "We", "believe",...
[ "We", "believe", "these", "factors", "have", "primarily", "driven", "the", "decline", "in", "the", "number", "of", "new", "customer", "starts", "which", "in", "turn", "began", "to", "hamper", "reactivation", "revenue", "." ]
[ "We", "believe", "these", "factors", "have", "primarily", "driven", "the", "decline", "in", "the", "number", "of", "new", "customer", "starts", "." ]
[]
[]
[ -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -1, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, -100, ...
[ -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1 ]